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List of Abbreviation  
 
aa Amino acid 
APS Ammonium persulfate 
Aqua dest. Distilled water 
bp Base pair 
BSA Bovine serum albumine 
CDK Cyclin-dependent kinase 
CSD Cold shock domain 
CSP Cold shock protein 
CspA/B Cold shock protein-A/-B 
CTCF CCCTC-binding factor 
DAB Diaminobenzidine 
DbpA/B/C DNA-binding protein-A/-B/-C 
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DTT Dithiothreitol 
FCS Fetal calf serum 
EDTA Ethylenediaminetetraacetic 
EGFR Epidermal growth factor receptor 
elF4E elongation initiation factor-4E 
Erk Extracellular signal-regulated kinases 
GEF-H1 Guanine nucleotide exchange factor-H1  
GM-CSF Granulocyte-macrophage colony stimulating factor 
GN Glomerulonephritis 
Grp78 Glucose regulated protein-78 
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HEK-293 Human embryonic kidney cells-293 
HIV Human immunodeficiency virus 
HK-2 Human kidney cells-2  
HKC-8 Human kidney clone-8 cells 
HLA Human leukocyte antigen 
HSC Hepatic stellate cells 
IFN Interferon 
IgA Immunglobulin-A 
IGFBP1 Insulin-like growth factor-binding protein-1 
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IL-13 Interleukin-13 
IRP2 Iron regulatory protein-2 
kb Kilobase 
kDa Kilodalton 
LPC Liver progenitor cells 
MAPK Mitogen-activated protein kinase  
MDR-1 Multi-drug resistance gene-1 
MEK MAP kinase kinase 
MHC Major histocompability complex 
MMP Matrix-metalloproteinase 
MRP1/2 Multidrug resistance-associated protein-1/-2 
MsGN Mesangioproliferative glomerulonephritis 
mRNA Messenger RNA 
Notch-3 Notch gene-3 
PBS Phosphate buffered saline 
PCNA Proliferating cell nuclear antigen 
PCR Polymerase chain reaction 
PDGF-B Platelet derived growth factor-B 
PTB Polypyrimidine tract binding protein 
PTP1B Protein tyrosine phosphatase-1B 
RNP Ribonucleoprotein particle 
rMC Rat mesangial cell 
rpm  Rotations per minute 
RANTES Regulated upon activation normal T cell expressed and secreted 
RPMI Roswell Park Memorial Institute 
RSV Rous Sarkom Virus 
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SMA Smooth muscle actin 
TEMED N,N,N’,N’-Tetramethylethylendiamine 
TF Transcription factor 
TGF-β Transforming growth factor-beta 
Tris 2-Amino-2-(hydroxymethyl)-1,3-propandiol 
TTBS Tris buffered solution/Tween-20 
Twist1 Twist gene-1 
UTR Untranslated region 
YB-1 Y-box binding protein-1  
ZO-1 Zonula occludens-1 
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1 Introduction 
 
1.1 Cold shock proteins   
 
Adaptation to environmental stress is essential for the survival of cells and living organisms. One of 
the most archtypical responses to a temperature downshift in microorganisms is the induction of 
cold shock proteins (CSPs). It was first reported in 1987 that in cultures of E. coli growing at 37 ○C 
a down-shift to 10 ○C alters protein synthesis. The synthesis was dramatically reduced except for 15 
proteins, the so-called cold shock proteins (CSPs) (Jones, VanBogelen et al. 1987). The major CSPs 
in E. coli (e.g. CspA and CspB) composites of a protein family showing single nucleic acid-binding 
cold shock domain (CSD) (Goldstein, Pollitt et al. 1990), in which two consensus RNA binding 
motifs are found (RNP-1 and RNP-2). CSPs may bind to and stabilize the secondary structures of 
RNA and DNA molecules, thereby they may reduce efficiency of mRNA translation and 
transcription. CSPs play important roles in cold shock stress adaptation of microorganisms 
(Thieringer, Jones et al. 1998). The cold shock domain (CSD) is evolutionarily conserved and is 
found in prokaryotes as well as eukaryotes, from bacteria to humans, as exemplified in Figure 1.  
 
 
Figure 1. Sequence alignment of cold shock domains (CSDs) of eukaryotic and prokaryotic cold shock proteins. 
RNA-binding motifs RNP-1 and RNP-2 are highlighted. Identical residues are depicted in black, homologous residues 
are in blue. Differences in conservation of residues between eukaryotes and prokaryotes are marked by arrows. (Kloks, 
Spronk et al. 2002) 
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Unlike bacteria, eukaryotic CSPs contain auxiliary domains. In eukaryotes, three structural domains 
are disdinguishable: (1) a small domain at the N-terminus, (2) a centrally localized cold shock 
domain (CSD) and (3) a C-terminal domain. Higher plant CSPs contain only two nucleic 
acid-binding modules: a single N-terminal CSD and variable numbers of C-terminal retroviral-like 
CCHC zinc fingers (Matsumoto and Wolffe 1998; Karlson and Imai 2003) (see Figure 2)  
 
Figure 2. Sequence features of cold shock proteins found in different species. Proteins are aligned at their CSDs. 
The C-terminal domains significantly differ in their organization.  
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The cold shock domain may approach RNA, single stranded as well as double stranded DNA 
(Newkirk, Feng et al. 1994; Schindelin, Jiang et al. 1994) and contributes to both transcriptional and 
translational functions. The C-terminal domain of CSPs shows significant variability (Figure 2): 
The C-terminal tail of human cold shock proteins and some other vertebrate CSPs consists of 
alternating regions of predominantly basic/acidic amino acids and may also bind to nucleic acid 
residues in isolation (Ladomery and Sommerville 1994). In the marine invertebrate Aplysia 
californica and in Drosophila melanogaster C-terminal domains lack acidic amino acids and 
contain multiple RNA-binding RGG repeats (Skehel and Bartsch 1994; Thieringer, Singh et al. 
1997). In Schistosoma mansoni the very basic tail domain is proposed to have a structure similar to 
that of fibroin that is predicted to contubute to nucleic acid binding (Franco, Garratt et al. 1997). In 
lower animals, such as Caenorhabditis elegans and in plants (e.g. wheat), the C-terminal domain 
contains zinc fingers (Moss, Lee et al. 1997). Protein-protein interactions of the N-terminal domain 
have been reported. For human CSPs an interaction with cytoskeleton actin is found (Ruzanov, 
Evdokimova et al. 1999). It is likely that auxiliary domains have been added to the CSD during 
evolution and that these contribute to nucleic-acid-binding specificities and protein-protein 
interaction.  
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1.2 Human cold shock proteins (DbpA, DbpB/YB-1 and DbpC) 
 
1.2.1 Structure analysis of human CSPs 
 
In humans CSPs were first identified as proteins binding to the epithelial growth factor receptor 
(EGFR) enhancer or c-erb-2 promoter and were denoted DNA-binding protein A (DbpA) and 
DNA-binding protein B (DbpB) (Sakura, Maekawa et al. 1988). From an independent group, DbpB 
was cloned as transcription factor that binds to the inverted CCAAT-box (the so-called Y-box) from 
the HLA-gene promoter (Didier, Schiffenbauer et al. 1988) and was denoted Y-box binding 
protein-1 (YBX1, YB-1). Thus leads to the names Y-box binding proteins or Y-box proteins.  
 
Later on DbpA was cloned and characterized as two isoforms (DbpA_a and DbpA_b) generated by 
alternative mRNA splicing (Kudo, Mattei et al. 1995). Given their interaction with tight junction 
protein zonula occludens-1 (ZO-1), they were also denoted ZO-1-associated nuclear acid binding 
protein (ZONAB) (Lima, Parreira et al.; Balda and Matter 2000). Another member of the human 
CSPs is Contrin (DbpC) (Tekur, Pawlak et al. 1999). DbpC is only expressed by germinal cells of 
the testis (see Figure 3). 
 
Figure 3. Domain organization of human cold shock protein family members. A/P: alanine- and proline-rich 
N-terminal domain; CSD: cold shock domain; B/A repeat: basic and acidic amino acid clusters; AD: alternative domain. 
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Since DbpC/Contrin expression is restricted to germinal cells most of the studies carried out in 
human cold shock proteins are devoted to DbpA and DbpB/YB-1 expression and functions. 
Alignment of protein sequences of DbpA and DbpB/YB-1 from different vertebrate species (human, 
chimp, mouse, rat, cow and dog) shows that the central cold shock domain has close to 100% 
conservation. The C-terminal domain contains some homologous islands. The N-terminal domains 
of DbpA and DbpB/YB-1 are quite distinct from each other (Figure 4). These similarities possibly 
indicate that DbpA and DbpB/YB-1 share some common functions mediated by the central CSD or 
the C-terminus. Different activities may be contributed by the N-terminal domains. DbpA and 
DbpB/YB-1 in rat and mouse are highly conserved, 85% and 95% identites respectively. 
 
 
 
Figure 4. Protein sequence alignment of DbpA and DbpB/YB-1 from different species. Protein homology becomes 
apparent when human, chimp, cow, mouse and rat proteins are compared;. Identity is indicated by dark blue; 
homologous residues are in light blue. Alternative domain is boxed in yellow. 
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1.2.2 Human CSPs as DNA and RNA binding proteins 
 
By virtue of nucleic acid binding activities DbpA and DbpB/YB-1 may alter gene transcription in 
the nucleus, affect pre-mRNA splicing as well as mRNA translation processes within the nucleus 
and cytoplasm (Matsumoto and Wolffe 1998). Of importance, the binding motifs that DbpA and 
YB-1 recognize are not limited to the inverted CCAAT-box (Y-box). Many studies revealed that 
cold shock proteins rather recognize DNA or RNA structural motifs than a defined nucleotide 
sequence, and may furthermore exert modifying steps to the nucleic acid backbones. In this regard 
it is compelling to observe that DbpA/YB-1 protein may propagate separation of double-stranded 
DNA and stabilize single-stranded loops (MacDonald, Itoh-Lindstrom et al. 1995; Mertens, 
Alfonso-Jaume et al. 1998; Norman, Lindahl et al. 2001). It has been reported that the C-terminal 
tail domain is required for homo-multimerization of vertebrate CSPs and this domain facilitates 
binding to DNA and RNA (Nambiar, Swamynathan et al. 1998; Swamynathan, Nambiar et al. 
1998). The alternating blocks of basic and acidic amino acids has led to the interesting proposal that 
this domain functions as a charged-zipper to mediate protein–protein interactions (Ozer, Faber et al. 
1990). This type of sequence is a common feature in proteins that contain nuclear localization 
sequences (NLS), bind to ribonucleoprotein complexes and shuttle between the nucleus and 
cytoplasm (Meier and Blobel 1992; Matsumoto and Wolffe 1998). Gene regulation mechanisms of 
YB-1 at both transcriptional and translational levels are summarized in Figure 5 (Kohno, Izumi et al. 
2003).  
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Figure 5. Transcriptional and translational gene regulation by CSPs. A: CSPs directly bind to Y-boxes or related 
sequences. B: CSPs interact with other TFs and functions as either co-activator or co-repressor. C: CSPs bind to the 
single-stranded region of the promoter either to enhance or inhibit the DNA binding of TFs. D: CSPs may bind to 
mRNA to inhibit the access of Cap binding factor (e.g. elF4E) and repress translation, a process denoted mRNA 
masking. E: A specific model is via protein-protein interactions. IRP2 binds to the 5’UTR of ferritin mRNA and 
inhibits translation. Interaction of CSPs and IRP2 leads to release of these complexes from mRNA. Thereby it becomes 
accessible for translation. CSD: cold shock domain; TF: transcription factor 
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Defined target genes of DbpA and DbpB/YB-1 are summarized in Table 1 and Table 2 respectively 
(  indicates up-regulation;  indicates down-regulation). Most studies have focused on 
DbpB/YB-1, given its conserved amino acids compositions throughout evolution. However, 
recently efforts are devoted to unravel functions of DbpA (Buchert, Darido et al. 2009; Lima, 
Parreira et al. 2010).  
 
 
Table 1. Target genes regulated by DbpA.  
Gene Regulation References 
Cytokines, Chemokines and Receptors 
EGFR/HER2  (Sakura, Maekawa et al. 1988) 
IGFBP1  (Tobita, Kajino et al. 2006) 
GM-CSF  /  (Coles, Diamond et al. 1996) 
Megalin  (Lima, Parreira et al. 2010) 
Cubilin  (Lima, Parreira et al. 2010) 
Antigen Presentation 
HLA class II  (Didier, Schiffenbauer et al. 1988) 
HLA class I  (Lloberas, Maki et al. 1995) 
Proliferation 
PCNA  (Sourisseau, Georgiadis et al. 2006) 
Cyclin D1  (Sourisseau, Georgiadis et al. 2006) 
Viral Promoters 
RSV  (Swamynathan, Nambiar et al. 1998) 
Others 
Grp78  (Li, Hsiung et al. 1997) 
Table 2: Target genes regulated by DbpB/YB-1. 
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Gene Regulation References 
Cytokines, Chemokines and Receptors 
EGFR/HER2  (Wu, Lee et al. 2006) 
PDGF-B  (Stenina, Poptic et al. 2000) 
RANTES  (Krohn, Raffetseder et al. 2007) 
IFN-alpha & IFN-beta  (Yan and Tamm 1991) 
GM-CSF  /  (Coles, Diamond et al. 1996) 
Thyrotropin Receptor  (Ohmori, Shimura et al. 1996) 
Signal Transduction 
Smad7  (Dooley, Said et al. 2006) 
PTP1B  (Fukada and Tonks 2003) 
Matrix and Matrix-Degrading Proteins 
Gelatinase A (MMP-2)  /  (Mertens, Harendza et al. 1997) 
Collagen Type 1 (alpha1) /  (Norman, Lindahl et al. 2001; Higashi, Inagaki et al. 
2003)  
Structural Proteins and others 
Myosin light-chain 2v  (Zou, Evans et al. 1997) 
Cyclin A and B1  (Jurchott, Bergmann et al. 2003) 
Globin  (Knezetic and Felsenfeld 1993) 
α-SMA  (Zhang, Liu et al. 2005) 
Antigen Presentation 
HLA class II  (Didier, Schiffenbauer et al. 1988) 
HLA class I  (Lloberas, Maki et al. 1995) 
Proliferation 
DNA-Polymerase-alpha  (En-Nia, Yilmaz et al. 2005) 
c-myc  (Chernukhin, Shamsuddin et al. 2000) 
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Transport Proteins, Detoxification 
MDR-1  (Bargou, Jurchott et al. 1997) 
MRP1  (Chansky, Hu et al. 2001) 
MRP2  (Geier, Mertens et al. 2003) 
Grp78  (Li, Hsiung et al. 1997) 
Viral Promoters 
RSV  (Swamynathan, Nambiar et al. 1998) 
HTLV-1  (Kashanchi, Duvall et al. 1994) 
HIV  (Ansari, Safak et al. 1999) 
JC Polyomavirus  (Safak and Khalili 2001) 
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1.2.3 Protein-protein interactions of human CSPs 
 
Biological functions of DbpA and DbpB/YB-1 are extended further due to interactions with partner 
proteins or other co-factors. The following protein-protein interactions of DbpA are summarized in 
Table 3. Much more studies have focused on the interacting partners of DbpB/YB-1, and known 
characters are summarized in Table 4. 
 
Table 3: Protein-protein interactions of DbpA 
Interacting Protein Relevance of interaction References 
Phosphorylation 
Erk/RSK phosphorylates S134 (Sears, Luong et al. 2010) 
mRNA Translation 
symplekin mRNA translation (Buchert, Darido et al. 2009) 
GEF-H1  mRNA translation (Nie, Aijaz et al. 2009) 
PTB VEGF mRNA stabilization (Coles, Bartley et al. 2004) 
Cytoskeleton  
ZO-1 Tight-junction signaling (Balda, Garrett et al. 2003) 
Cell cycling 
CDK4/CDK5 Cell cycling (Moorthamer, Zumstein-Mecker et al. 
1999) 
 
Table 4: Protein-protein interactions of DbpB/YB-1 
Interacting Protein Relevance of interaction References 
Phosphorylation 
Akt phosphorylates S102 (Sutherland, Kucab et al. 2005) 
Casein kinase II phosphorylation (Skabkin, Kiselyova et al. 2004) 
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Co-Transcription factor 
AP-2  MMP-2 transcription (Mertens, Alfonso-Jaume et al. 1998)
CTCF  c-myc transcription (Chernukhin, Shamsuddin et al. 2000)
Agno-protein (JC virus) viral gene transcription (Safak, Sadowska et al. 2002) 
Nm23-ß  MMP-2 transcription (Marenstein, Ocampo et al. 2001) 
p53 p21 and MMP-2 transcription (Chen, Gherzi et al. 2000) 
Pur α a-SMA transcription (Ansari, Safak et al. 1999) 
p300/Smad3 collagen gene transcription  (Dooley, Said et al. 2006)  
RelA (p65) viral gene transcription (Raj, Safak et al. 1996) 
T-antigen (JC virus) viral gene transcription (Ansari, Safak et al. 1999) 
mRNA Transport, stabilization and splicing 
Actin mRNA transport (Ruzanov, Evdokimova et al. 1999) 
hnRNP K  mRNA transport (Shnyreva, Schullery et al. 2000) 
Nucleolin IL-2 mRNA stabilization (Chen, Gherzi et al. 2000) 
SRp30c  mRNA splicing (Raffetseder, Frye et al. 2003) 
TLS  mRNA splicing (Chansky, Hu et al. 2001) 
PTB VEGF mRNA stabilization (Coles, Bartley et al. 2004) 
Microtubulules mRNA transport (Chernov, Curmi et al. 2008) 
Others  
EGFR  enhance EGFR signaling (Berquin, Pang et al. 2005) 
Endonuclease III DNA repair (Marenstein, Ocampo et al. 2001) 
Notch-3 receptor receptor activation (Rauen, Raffetseder et al. 2009) 
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1.2.4 Sub-cellular localization of human CSPs 
 
The functions fulfilled by human CSPs take place in different sub-cellular compartments: nucleus, 
cytoplasm as well as extracellularly. Nuclear translocation of CSPs to activate target genes 
transcription is found with epithelial cell proliferation. For instance, DbpA releasing from tight 
junctions and shuttling to the nucleus is observed in proliferating renal tubular cells (Sourisseau, 
Georgiadis et al. 2006) and intestinal goblet cells (Buchert, Darido et al. 2009). DbpA nuclear 
accumulation in hepatocellular carcinoma cells is associated with poor outcome (Yasen, Kajino et al. 
2005), while similar phenomena of DbpB/YB-1 nuclear localization is also detected in various 
cancer diseases, e.g. breast cancer (Kashihara, Azuma et al. 2009) and non-small cell lung cancer 
(Gessner, Woischwill et al. 2004). However, the activities of nuclear CSPs in mesenchymal cells 
may be distinct from epithelial cells. In mesangial cells, DbpB/YB-1 nuclear accumulation is found 
in healthy control tissues without cell proliferation (van Roeyen, Eitner et al. 2005). In addition, 
DbpB/YB-1 nuclear accumulation in hepatic stellate cells functions as an anti-fibrotic factor by 
stimulation of Smad7 transcription (Dooley, Hamzavi et al. 2008).  
 
On the other hand, human CSPs localized in the cytoplasm regulate translation, e.g. of VEGF 
(Coles, Bartley et al. 2004), IL-2 (Chen, Gherzi et al. 2000), GM-CSF (Capowski, Esnault et al. 
2001) and TGF-β transcripts (Fraser, Phillips et al. 2008) In cancer tissue of different origins, 
staining of cytoplasmic DbpA and DbpB/YB-1 is often detected (Bergmann, Royer-Pokora et al. 
2005; Yasen, Kajino et al. 2005). In addition, cytoplasmic accumulation of DbpB/YB-1 is observed 
within mesangial cells of animals suffering from mesangioproliferative disease. This suggests that 
cytoplasmic CSPs may regulate cell proliferation at the post-transcriptional level (van Roeyen, 
Eitner et al. 2005).  
 
Recently, DbpB/YB-1 has been reported to be released to the extracellular space through a 
non-classical secretion pathway. Exteracellularly it may interact with the domains of receptor 
Notch-3 (Frye, Halfter et al. 2009; Rauen, Raffetseder et al. 2009). 
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Taken together, DbpA and DbpB/YB-1 may function as transcription factors in the nucleus, as 
translation factors in the cytoplasm, as well as mitogens or chemoattractants in the extracellular 
compartment (Figure 6).  
Figure 6. DbpA and DbpB/YB-1 localization and relevant functions.  
 
 - 21 - 
1.2.5 Regulation of CSP expression, modification and shuttling 
 
The major regulation mechanisms contributing to bacterial CSP CspA accumulation appear to be at 
the post-transcriptional level (Gualerzi, Giuliodori et al. 2003). There is an unusually long 5’UTR in 
CspA mRNA, which plays an important role in stabilizing CspA transcripts and enhancing 
translational activity at low temperature (Mitta, Fang et al. 1997). Human CSPs expression is 
similarly controlled at the translational level. It has been reported that DbpB/YB-1 auto-regulates its 
own mRNA translation by binding to a 3’UTR regulatory element (Skabkina, Lyabin et al. 2005). 
Human CSP genes lack typical eukaryotic regulatory sequences, such as TATA and CCAAT boxes, 
instead contains E-boxes and GATA motifs. Transcription factors containing 
the basic-helix-loop-helix structural motif typically approach E-boxes and regulate transcription. 
Several of them have been reported to be involved in the up-regulation of human CSP transcription, 
e.g. c-myc (Uramoto, Izumi et al. 2002; Li, Van Calcar et al. 2003), Math2 (Ohashi, Fukumura et al. 
2009) and Twist1 (Shiota, Izumi et al. 2008; Shiota, Izumi et al. 2008). Programmed cell death 
protein 4 (PDCD4) and p53 are reported to regulate DbpB/YB-1 expression by directly interacting 
with Twist1 (Shiota, Izumi et al. 2008; Shiota, Izumi et al. 2009). Besides E-boxes, a functional 
GATA motif is found in human CSP promoter sequences. DbpB/YB-1 is transcriptionally regulated 
by GATA-1, which is crucially involved in erythroid differentiation (Yokoyama, Harigae et al. 
2003). In addition, DbpA gene transcription is enhanced by E2F1, which seems to be relevant in 
hepatocarcinogenesis (Arakawa, Kajino et al. 2004). 
 
Concerning upstream events different growth factors, cytokines and signaling pathways are 
involved in the regulation of human CSP. DbpB/YB-1 protein expression is induced by various 
stimuli, e.g. PDGF-B (van Roeyen, Eitner et al. 2005), TGF-β (Feng, Huang et al. 2009) and IL-2 
(Sabath, Podolin et al. 1990). The MAPK/ERK pathway mediates PDGF-B effects and thereby 
up-regulates DbpB/YB-1 expression (van Roeyen, Eitner et al. 2005; Feng, Huang et al. 2009).  
 
Numerous studies show nuclear shuttling of DbpB/YB-1 in the cells that stressed by UV light, 
hyperthermia (Ohga, Koike et al. 1996) or stimulated with cytokines (like IFN-gamma, IGF-1) and 
thrombin (Stenina, Poptic et al. 2000; Higashi, Inagaki et al. 2003). Two distinct mechanisms may 
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be involved: 1. Thrombin induces signals with DbpB/YB-1 cleavage. The resultant protein 
C-terminal fragment contains a cytoplasmic retention signal (CRS). The N-terminal protein 
fragment on the other hand shuttles into the nucleus (Stenina, Poptic et al. 2000; Stenina, Shaneyfelt 
et al. 2001). The 20S proteasome is considered to be a mediator of this cleavage event (Sorokin, 
Selyutina et al. 2005). Within the highly conserved CSD a phosphorylation site (Ser134 within 
DbpA and Ser102 within DbpB/YB-1) has been identified as substrate of PI3K/Akt (Bader, Felts et 
al. 2003; Sutherland, Kucab et al. 2005) or ERK/RSK (Coles, Lambrusco et al. 2005; Stratford, Fry 
et al. 2008). Studies with breast cancer cells from the group of Prof. Dunn (Vancouver, Canada) show 
that Ser102 phosphorylation of DbpB/YB-1 mediates nuclear translocation (Sutherland, Kucab et al. 
2005; Stratford, Fry et al. 2008; Dhillon, Astanehe et al. 2010). Of note, studies from Evdokimova 
and colleagues reveal that Akt-mediated phosphorylation of Ser102 within DbpB/YB-1 is critical 
for its translational activities (Evdokimova, Ovchinnikov et al. 2006; Evdokimova, Ruzanov et al. 
2006). Ser102 phosphorylation of DbpB/YB-1 reduces its affinity to capped 5’ terminus of mRNA 
and releases mRNA for translation. The phosphorylated DbpB/YB-1 dissociates from mRNA and 
may shuttle to nucleus, as observed by Dunn’s group.  
 
Besides nuclear translocation, DbpB/YB-1 may also shuttle from the nucleus to the cytoplasm, as 
observed in a rat model of mesangioproliferative nephritis. PDGF-B with MAPK/ERK signaling are 
considered to play roles in this nuclear-cytoplasm translocation, but the mechanisms are still unclear 
(van Roeyen, Eitner et al. 2005). Furthermore PDGF-B may induce DbpB/YB-1 secretion by 
mesangial and inflammatory cells (Frye, Halfter et al. 2009; Rauen, Raffetseder et al. 2009).  
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1.3 Biological functions of human CSPs 
 
Human CSPs direct gene transcription (Jurchott, Bergmann et al. 2003), DNA replication (En-Nia, 
Yilmaz et al. 2005), DNA repair (Das, Chattopadhyay et al. 2007), mRNA stablization and 
translation (Evdokimova, Ruzanov et al. 2006), drug resistance (Chattopadhyay, Das et al. 2008), 
cytokines (Chen, Gherzi et al. 2000; Capowski, Esnault et al. 2001) and matrix synthesis (Mertens, 
Harendza et al. 1997; Norman, Lindahl et al. 2001). CSP DbpA and DbpB/YB-1 share biological 
roles differences become apparent. The common biological functions are summarized below, 
difference will be emphasized thereafter.  
 
1.3.1 Promote cell proliferation and carcinogenesis  
 
Most effort of human CSPs studies have been paid to their roles in cell proliferation and 
carcinogenesis, since over-expression of DbpA or DbpB/YB-1 have be detected in various cancer 
diseases, e. g. breast cancer (Bargou, Jurchott et al. 1997; Bergmann, Royer-Pokora et al. 2005), 
non-small cell lung carcinoma (Gessner, Woischwill et al. 2004), ovarian adenocarcinomas 
(Kamura, Yahata et al. 1999; Oda, Ohishi et al. 2007), human osteosarcomas (Oda, Sakamoto et al. 
1998; Oda, Ohishi et al. 2003), colorectal carcinomas (Shibao, Takano et al. 1999; Vaiman, 
Stromskaya et al. 2007), malignant melanomas (Schittek, Psenner et al. 2007), leukemia (Sears, 
Luong et al. 2010) and hepatocellular carcinoma (Yasen, Kajino et al. 2005). On the other hand, 
growth-promoting effects of human CSPs are not restricted to cancer diseases. Recent studies in 
kidney ontogeny show that DbpA-expressing renal tubulal cells are highly proliferative (Lima, 
Parreira et al. 2010).  
 
- Underlying mechanisms: 
 
1. Human CSPs promote cell proliferation and carcinogenesis by inducing cell cycle regulatiory 
proteins, e.g. DbpA induces cyclin D1 and PCNA (Sourisseau, Georgiadis et al. 2006);  
DbpB/YB-1 activates cyclin A and cyclin B1 (Jurchott, Bergmann et al. 2003). DbpB/YB-1 may 
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also directly interact with cyclin D1 (Khandelwal, Padala et al. 2009) and PCNA (Ise, Nagatani et al. 
1999). 
 
2. Human CSPs may regulate signaling pathways that guide cell proliferation. EGF signaling plays 
a role in the progression of breast cancer, cell growth EGF receptor (EGFR) and Her-2 have been 
regarded as important prognostic markers. Human CSP may bind to the EGFR and Her-2 promoter 
regions and enhance gene expression (Sakura, Maekawa et al. 1988; Stratford, Habibi et al. 2007). 
Elevated DbpB/YB-1 levels in breast cancer samples correlate with EGFR expression and poor 
outcome. In addition, EGF signaling may induce DbpB/YB-1 nuclear translocation (Berquin, Pang 
et al. 2005). The later may indicate a positive feedback loop promoting cell proliferation (Brandt, 
Raffetseder et al. 2011). Similar regulatory mechanisms were found for PDGF signaling (van 
Roeyen, Eitner et al. 2005; Zhang, Liu et al. 2005).  
 
3. During the pathogenesis of human hepatocellular carcinoma (HCC), hepatitis virus B and C 
infection is major contributor. Hino’s group reported DbpA and DbpB/YB-1 are binding partners of 
HBV DNA fragment (nt1855-1914), that human CSPs may contribute to the recombination of HBV 
and human DNA, cause genomic instability and enhance HCC occurrence (Kajino, Yamamoto et al. 
2001).  
 
4. Human CSPs may promote cell proliferation and carcinogenesis by regulating other 
proliferation-associated genes, e.g. thymidine kinase (Kim, Lau et al. 1997), DNA 
polymerase α (En-Nia, Yilmaz et al. 2005), c-myc (Kolluri and Kinniburgh 1991) and p53 (Homer, 
Knight et al. 2005). 
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1.3.2 Repress cell differentiation 
 
Human CSP may repress cell differentiation and thereby contribute to tumorogenesis and other 
diseases, e.g. refractory anemia (Yokoyama, Harigae et al. 2003). During kidney ontogeny and 
polarization of proximal tubular cells, DbpA protein levels decrease in parallel and inversely with 
progressing apical differentiation. The expression of renal tubular cell specific antigens megalin and 
cubilin are suppressed by DbpA (Lima, Parreira et al. 2010). In intestinal goblet cells acute myeloid 
leukemia-1 (AML1) protein has been identified as a promoter of intestinal differentiation mediated 
by Kruppel-like factor 4 (KLF4) signaling. In cooperation with symplekin, DbpA is found be a 
transcriptional repressor that directly binds to the promoter of the AML1 gene, thus inhibiting 
intestinal differentiation as confirmed both in vitro and in vivo (Buchert, Darido et al. 2009). DbpA 
also plays an important role during fetal erythropoiesis. Production of fetal haemoglobin is 
inversely correlated to DbpA expression, since DbpA directly binds to the hemoglobin-2 (HGB2) 
promoter and suppresses its transcription (Horwitz, Maloney et al. 1994; Petruzzelli, Gaudino et al. 
2010). DbpB/YB-1 was reported to function as a negative regulator of myoblast differentiation by 
suppressing α-SMA gene transcription (Zhang, Liu et al. 2005) or by interacting with Msh 
homeobox 1 (Msx1) (Song and Lee 2010). Other reports show DbpB/YB-1 is negatively related to 
neural stem cells (Fotovati, Abu-Ali et al. 2011) and erythroid cell differentiation (Yokoyama, 
Harigae et al. 2003; Bhullar and Sollars 2011). In addition, DbpA may also regulate muscle cell 
differentiation. cdk5 kinase, with p35 as its activator, has been demonstrated to be responsible for 
muscle cells differentiation (Philpott, Porro et al. 1997). Either over-activation or blockage of 
cdk5/p35 expression may result in muscle disruption, therefore cdk5 kinase activity should be 
balanced/blocked during terminal differentiation of muscle cells. One possible mechanism would 
envision DbpA directly interacting with cdk5 and acting as a competitor of p35 (Moorthamer, 
Zumstein-Mecker et al. 1999). This assumption is partially supported by the fact that DbpA is 
highly expressed in skeletal and heart muscle cells as compared to other tissues (Kudo, Mattei et al. 
1995; Moorthamer, Zumstein-Mecker et al. 1999). 
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1.3.3 Involved in cell-cell communication and cytoskeleton formation 
 
Human CSPs are involved in the fine tuning of cell-cell communication, early-on recognized given 
their effects on major histocompatibility complex (MHC) I-A beta (Lloberas, Maki et al. 1995). 
Human CSPs directly regulate the expression of cytokines, e.g. granulocyte-macrophage 
colony-stimulating factor GM-CSF (Coles, Diamond et al. 1996; Coles, Diamond et al. 2000; 
Diamond, Shannon et al. 2001), IL-2 (Chen, Gherzi et al. 2000) and TGF-β (Fraser, Phillips et al. 
2008; Jenkins, Bennagi et al. 2010) , as well as receptors, e.g. EGFR (Sakura, Maekawa et al. 1988); 
Recently, DbpB/YB-1 has reported to be exported to the extracellular space through a non-classical 
secretion pathway and may interact with the extracellular domain of Notch-3 receptor (Frye, Halfter 
et al. 2009; Rauen, Raffetseder et al. 2009). It indicates DbpB/YB-1 may also functions as a 
mitogen or chemoattractant in the extracellular compartment. 
 
Tight and gap junctions, are of great importance for cell-cell communication of neighboring cells. 
Numerous studies reveal that DbpA is localized within tight junctions (TJ) and regulates 
TJ-associated activities. Balda and Matter first identified the cooperation of DbpA with zonula 
occludens 1 (ZO-1) protein, one of the major components of TJ (Balda and Matter 2000); Later on, 
two additional TJ-associated proteins were identified as partners of DbpA, symplekin (Kavanagh, 
Buchert et al. 2006) and GEF-H1 (Nie, Aijaz et al. 2009). Several other TJ-associated proteins have 
been reported to be involved in the orchestration of DbpA activities at TJ, e.g. heat-shock protein 
Apg-2 (Tsapara, Matter et al. 2006), B-cell lymphoma 2 (Bcl-2) (Li, Backer et al. 2003), 
Ras-related protein Ral-A (Frankel, Aronheim et al. 2005) and blood vessel epicardial substance 
(Bves) (Russ, Pino et al. 2011). DbpA-ZO-1 complex at the TJ regulates paracellular permeability. 
When DbpA is released from the TJ by competitive binding, smodification or TJ disruption, it may 
form complexes with symplekin and GEF-H1, translocate to the nucleus and thereby affect cell 
proliferation and differentiation as a transcription factor. This mechanism has been confirmed by 
several studies in vivo (Pannequin, Delaunay et al. 2007; Georgiadis, Tschernutter et al. 2010; Lima, 
Parreira et al. 2010). DbpA and ZO-1 also colocalize at oligodendrocyte and astrocyte gap junctions 
in mouse brain (Penes, Li et al. 2005). DbpA was found to be associated with oligodendrocytic 
connexin Cx47 and Cx32 proteins as well as with astrocytic Cx43. In Cx47 knock-out mice DbpA 
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was absent in oligodendrocytes (Li, Penes et al. 2008). These data suggest that DbpA may regulate 
glial gap junction associated signaling and activities.  
 
Hitherto no evidences exist that DbpB/YB-1 is involved in tight or gap junction formation. 
DbpB/YB-1 promotes microtubule assembly through interaction with tubulin and microtubule 
(Chernov, Mechulam et al. 2008). In addition, the N-terminal domain of DbpB/YB-1 may directly 
interact with actin and microfilaments (Ruzanov, Evdokimova et al. 1999). These interactions of 
DbpB/YB-1 with microtubules and microfilaments may play a role in mRNA transport, anchoring 
and localization with cytoskeleton elements.  
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1.3.4 Respond to cell stress and drug-resistance 
 
DbpB/YB-1 was found to be over-expressed in many drug resistant breast cancer patients. 
Multidrug resistance-1 (MDR-1) gene encodes for P-glycoprotein (an ABC transporter) believed to 
be responsible for multidrug resistance in cancer cells. DbpB/YB-1 is directly involved in MDR-1 
gene transcription in response to genotoxic stress, e.g. cisplatin, mitomycin C and UV radiation 
(Asakuno, Kohno et al. 1994; Ohga, Uchiumi et al. 1998). Another ABC transporter regulated by 
DbpB/YB-1 is Mrp2, which is down-regulated at the transcriptional level following stimulation 
with cytokines (Geier, Mertens et al. 2003). On the other hand, when mammalian cells are subjected 
to physiological stress targeting the endoplasmic reticulum (ER), cells activate a defense 
mechanism denoted “unfolded protein response” (UPR), which is evolutionarily conserved from 
yeast to humans (Foti, Welihinda et al. 1999). The major cellular response protein in UPR is an ER 
chaperone called Grp78 (Reddy, Mao et al. 2003). Grp78 not only binds to unfolded proteins but 
also regulates the activation of ER stress signal transducers, that protect stressed cells from 
apoptosis (Bertolotti, Zhang et al. 2000). DbpA and DbpB/YB-1 have been identified as 
transcriptional regulators that bind to the stress-inducible change region (SICR) of the Grp78 gene 
(Li, Hsiung et al. 1997). 
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1.3.5 Regulate angiogenesis, lymphangiogenesis and metastasis formation 
 
Roles of human CSP in angiogenesis and lymphangiogenesis are easily envisioned given the direct 
effects on vascular endothelial growth factor (VEGF) expression. In 2002, Coles and the colleagues 
first reported DbpA as a transcriptional repressor of the VEGF-A gene. DbpA interacts with 
hypoxia inducible factor-1 (HIF-1) and targets the hypoxia-responsive element (HRE) within the 
VEGF-A promoter (Coles, Diamond et al. 2002). This mechanism requires DbpA phosphorylation 
of the N-terminal domains by ERK2 and GSK3b (Coles, Lambrusco et al. 2005). 
Post-transcriptional regulation of VEGF by DbpA and DbpB/YB-1 occurs given binding to mRNA 
in cooperation with polypyrimidine tract binding (PTB) RNA proteins (Coles, Bartley et al. 2004). 
DbpA may represses angiogenesis mediated by VEGF-A, co-confirmed by two groups from Japan 
(Saito, Nakagami et al. 2008; Matsumoto, Yajima et al. 2010; Saito, Nakagami et al. 2011). In 
addition, DbpA represses transcription of VEGF-C gene expression via targeting to the serum 
response element (SRE) within the promoter (Saito, Nakagami et al. 2008; Matsumoto, Yajima et al. 
2010). Considering VEGF-C is a major growth factor for lymphatic endothelial cells. 
 
These results indicate that CSP repress angiogenesis and lymphangiogenesis. However, various 
studies indicate that high-expression of DbpA or DbpB/YB-1 in cancer cells goes along with 
invasive properties (Yasen, Kajino et al. 2005; Wang, Zheng et al. 2009). CSP may promote tumor 
cell metastasis by binding and modulating the activity of metastasis susceptibility gene ribosomal 
RNA processing 1 homolog B (Rrp1b) (Crawford, Yang et al. 2009) or by up-regulating expression 
of metastasis promoting proteins, e.g. gelatinase A (Mertens, Alfonso-Jaume et al. 1998), MUC1 
(Shiraga, Winpenny et al. 2005) and snail (Evdokimova, Tognon et al. 2009). Contradictory roles of 
human CSP with promotion or suppression of metastasis formation may be reconciled by distinct 
functions in different cell types. Repression of VEGF expression by human CSPs is observed in 
fibroblasts, while invasive cancer cells with CSP overexpression predominantly represent epithelial 
cells. 
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1.4 Human CSPs in inflammatory diseases 
 
Inflammatory diseases are characterized by a complex biological response of tissue to harmful 
stimuli, such as pathogens, damages and irritants. Inflammation can be classified as 
either acute or chronic. Acute inflammation is the initial response of the body to harmful stimuli 
with increased movement of plasma proteins and leukocytes (e.g. monocytes and granulocytes) 
from the blood into injured tissue. If the condition causing acute inflammation is not resolved, 
inflammation may transit into a chronic phase with fibrogenesis. Some pathogens by their enduring 
and self renewing nature provoke chronic inflammation, e.g. autoimmune diseases. The primary 
cells of chronic inflammation are monocytes/macrophages and lymphocytes. A cascade of 
biochemical events mediates the inflammatory response, involving the local vascular 
system, immune system and various cell-types within the injured tissue. Although studies on human 
CSP are often focused on malignant diseases, many of the biological functions summarized in the 
previous paragraphs indicate that CSP also play important roles in inflammatory diseases, e.g. of 
the kidney and liver. 
 
1.4.1 Human CSPs regulate cytokine expression 
 
CSP directly regulate the expression of various inflammatory cytokines. IL-2 is synthesized and 
secreted by activated T-cells, stimulates the differentiation and survival of antigen-selected 
cytotoxic T-cells and the maturation of regulatory T-cells. This is of great importance for 
autoimmune and chronic inflammatory diseases (Taniguchi and Minami 1993). It has been reported 
that DbpB/YB-1 may directly bind to and stabilize IL-2 mRNA following T-cell activation and 
thereby translationally regulate IL-2 expression (Chen, Gherzi et al. 2000). Stimulation of T helper 
lymphocytes with IL-2 induces DbpB/YB-1 expression (Sabath, Podolin et al. 1990). This may 
indicate the existence of an auto-stimulatory feedback loop of IL-2 and DbpB/YB-1 (Brandt, 
Raffetseder et al. 2011). Besides IL-2 in T-cells, DbpB/YB-1 may also directly stabilize and 
up-regulate the translation of GM-CSF transcript in activated eosinophils, that prolongs their 
survival (Capowski, Esnault et al. 2001). DbpA and DbpB/YB-1 were reported to suppress 
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GM-CSF gene transcription in embryomic lung fibroblasts (Coles, Diamond et al. 1996). This may 
indicate a cell-type specific regulatory mechanism. Similar events are reported for 
monocytes/marcrophages during cell differentiation and RANTES/CCL5 gene transcription 
(Raffetseder, Rauen et al. 2009). DbpB/YB-1 also controls TGF-β translation in proximal tubule 
cells (Fraser, Phillips et al. 2008; Jenkins, Bennagi et al. 2010) and PDGF-B transcription in 
endothelial cells (Stenina, Poptic et al. 2000). 
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1.4.2 Human CSPs in inflammatory kidney diseases 
 
In human biopsies from kidney transplant patients undergoing a rejection episode, DbpB/YB-1 
transcripts were found to be amplified 17-fold in acute and 21-fold in chronic allograft rejection 
compared to control tissue. This up-regulation closely correlates with RANTES/CCL5 mRNA 
expression under both conditions (Raffetseder, Rauen et al. 2009). DbpB/YB-1 is a cell-type 
specific regulator of RANTES/CCL5 expression in infiltrating T-cells and monocytes/macrophages 
(Raffetseder, Rauen et al. 2009).  
 
DbpB/YB-1 has also been identified as an important mediator/regulator in mesangioproliferative 
glomerulonephritis. DbpB/YB-1 functions as a downstream signaling target of PDGF-B and 
mediates a mitogenic effect in mesangioproliferative glomerulonephritis (van Roeyen, Eitner et al. 
2005). In healthy kidney cells, DbpB/YB-1 is predominantly localized within the nucleus. 
Subsequent to PDGF-B infusion and in the course of anti-Thy1.1 model re-localization of 
DbpB/YB-1 into the cytoplasm is observed and coincides with up-regulation of DbpB/YB-1 protein 
within the mesangial compartment. These events are dependent on PDGF-B signaling via the 
MAPK pathway because these alterations were prevented by specific PDGF aptamers and the 
MAPK pathway inhibitor U0126. In experimental models that lack profound mesangial cell 
proliferation (e.g., Puromycin-nephrosis, passive Heyman nephritis, spontaneous normotensive 
nephrosclerosis, hyperlipidemic diabetic nephropathy) DbpB/YB-1 localization was nuclear (van 
Roeyen, Eitner et al. 2005). There is evidence that DbpB/YB-1 is secreted by mesangial cell upon 
cytokine challenge via a non-classical secretion mode (Frye, Halfter et al. 2009). Secreted 
DbpB/YB-1 is a non-conventional ligand for receptor Notch-3 (Rauen, Raffetseder et al. 2009). Of 
interests, extracellular blockade of DbpB/YB-1 by application of an antibody potently induces 
receptor Notch-3 expression and signaling. This may indicate that DbpB/YB-1 controls Notch-3 
expression and signaling via an auto-regulatory feedback mechanism in mesangioproliferative 
diseases (Raffetseder, Rauen et al. 2011). 
 
The immunosuppressive calcineurin inhibitors (CNI) cyclosporine A (CsA) and tacrolimus are 
widely used in transplant organ recipients. In kidney allografts CNI may cause tubulointerstitial as 
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well as mesangial fibrosis. Recent study from our group shows that CsA and tacrolimus may induce 
DbpB/YB-1 expression in mesangial cells. This accumulation results in mRNA stabilization and 
contributes to renal fibrosis via subsequent generation of interstitial collagen fibers (Hanssen, Frye 
et al. 2011).  
 
On DbpA few studies have been performed in kidney diseases. A recent report reveals an inverse 
relationship between DbpA expression and apical proximal epithelial cells differentiation during 
kidney development (Lima, Parreira et al. 2010). Overexpression of DbpA prevents polarization 
and differentiation of proximal tubulules cells while promoting a proliferative phenotype. Thus, 
DbpA may play a role in renal tubular diseases.  
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1.4.3 Human CSPs in inflammatory liver diseases 
 
A close correlation of human CSP protein expression with hepatocellular carcinoma (HCC) 
formation is reported for the liver (Yasen, Kajino et al. 2005). Regardless of specific etiologies, 
most of the HCC patients are suffering from chronic inflammation with ensuing liver fibrosis. 
 
Transforming growth factor-β (TGF-β) is considered to be a major factor contributing to liver 
fibrogenesis. TGF-β and its intracellular mediators, Smad proteins, orchestrate collagen synthesis in 
hepatic stellate cells, the major collagen-synthenting celltype in the liver (Massague and Chen 
2000). Higashi and colleagues first described that nuclear translocation of DbpB/YB-1 antagonizes 
TGF-β/Smad3 signaling in hepatic stellate cells in vitro (Higashi, Inagaki et al. 2003; Higashi, 
Inagaki et al. 2003). Lateron, this anti-fibrotic effect was confirmed in vivo by adenovirus-mediated 
overexpression of DbpB/YB-1 driven by a collagen enhancer (Inagaki, Kushida et al. 2005) and by 
HSc025 stimulated nuclear translocation of DbpB/YB-1 (Higashi, Tomigahara et al. 2011). In 
addition, Dooley and colleagues revealed that DbpB/YB-1 is a potent inducer of Smad7 expression 
in activated hepatic stellate cells and that it antagonizes TGF-β signaling during chronic stages of 
fibro-proliferative diseases. Similar regulatory mechanisms were also observed in the kidney 
(Dooley, Said et al. 2006).  
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1.5 Aim of the study 
Cold shock proteins fulfill various biological functions considered to be important in inflammatory 
diseases. Only a few studies have been performed to delineate the expression pattern and underlying 
regulatory events in inflammatory diseases. In addition, most of the findings relate to DbpB/YB-1, 
but little is known about another prominent member denoted DbpA. The similarities and differences 
between these two human CSPs are largely unknown. To provide a more thorough insight into the 
expression pattern and regulatory mechanisms of cold shcok proteins in inflammatory kidney and 
liver diseases is the goal of the present work.   
Based on the former works from our group, that DbpB/YB-1 mediates PDGF-B effects in the 
mesangial cells of mesangioproliferative nephritis, the first part of the current study focuses on the 
expression patern and regulation of DbpA in this disease and to compare the findings with 
DbpB/YB-1.  
The second part of the current study is to elucidate the expression pattern(s) of the cold shock 
proteins in (chronic) inflammatory liver diseases as well as their regulatory events under the 
stimulation of pro-inflammatory factor, e.g. TGF-β and IL-13.  
 
In addition, different lengths of DbpA and DbpB/YB-1 promoter regions were cloned in order to 
reveal transcriptional regulatory mechanisms of human CSPs.  
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2 Materials and methods 
 
2.1 Reagents 
 
Cell culture reagents 
RPMI1640 medium          Invitrogen, Karlsruhe, Germany 
F-12/DMEM medium         Invitrogen, Karlsruhe, Germany 
DMEM medium          Invitrogen, Karlsruhe, Germany 
MCBD_201 medium         Sigma-Aldrich, Munich, Germany 
William’s E medium         Invitrogen, Karlsruhe, Germany 
 
Cell culture additives 
L-Glutamin           Lonza, Verviers, Belgium 
HBSS            PAA laboratories, Cölbe, Germany 
Fetal calf serum (FCS)        Invitrogen, Karlsruhe, Germany 
Insulin-transferrin-selenium (ITS)      Invitrogen, Karlsruhe, Germany 
Trypsin. 10X solution (2.5 %)       Invitrogen, Karlsruhe, Germany 
Penicillin/Streptomycin         Lonza, Verviers, Belgium 
 
Cytokines 
Human transforming growth factor-1 (TGF-β1)   Peprotech, London, UK. 
Platelet-derived growth factor-BB (PDGF-BB) Rat  Sigma-Aldrich, Munich, Germany 
Platelet-derived growth factor-BB (PDGF-BB) human  Sigma-Aldrich, Munich, Germany 
Insulin-like growth factor-II (IGF-II) human    Peprotech, London, UK. 
Epidermal growth factor (EGF)       BDBiosciences, Heidelberg, Germany 
 
Chemicals 
DMSO. Dimethylsulfoxide        Sigma-Aldrich, Munich, Germany 
Triton X-100           Sigma-Aldrich, Munich, Germany 
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Tris, Tris(hydroximethyl)aminomethane     Bio-Rad Laboratories, Munich, Germany  
SDS, Sodium dodecylsulfate        Bio-Rad Laboratories, Munich, Germany 
DTT, Dithiothreit          Bio-Rad Laboratories, Munich, Germany 
Tween20 solution          Bio-Rad Laboratories, Munich, Germany  
β-mercaptoethanol          Merck, Darmstadt, Germany  
Hepes             Roth, Karlsruhe, Germany 
Complete protease inhibitor cocktail      Roche, Mannheim, Germany 
Phosphatase inhibitor cocktail       Sigma-Aldrich, Munich, Germany 
PMSF             Roche, Mannheim, Germany 
10X transfer buffer solution        Invitrogen, Karlsruhe, Germany 
MOPS             Applichem, Darmstadt, Germany 
Ponceau S            Sigma-Aldrich, Munich, Germany 
TCA, Trichloroacetic acid        Sigma-Aldrich Munich, Germany 
PBS. Plus calcium and magnesium      Biochrom AG, Berlin, Germany 
Phenol/Chlorophorm/Isoamylalcohol      Roth, Karlsruhe, Germany 
Na-acetate            Sigma-Aldrich, Munich, Germany 
Isopropanol           Merck, Darmstadt, Germany 
Ethanol            Merck, Darmstadt, Germany 
Methanol            Merck, Darmstadt, Germany 
Hydrogen peroxide. 30 % (w/w)       Sigma-Aldrich, Munich, Germany 
Acetone            Merck, Darmstadt, Germany 
NaOH             Merck, Darmstadt, Germany 
HCl             Merck, Darmstadt, Germany 
NaCl             Merck, Darmstadt, Germany 
KCl             Merck, Darmstadt, Germany 
MgSO4            Merck, Darmstadt, Germany 
MgCl2             Merck, Darmstadt, Germany 
EDTA             Bio-Rad Laboratories, Munich, Germany 
Na-citrate            Merck, Darmstadt, Germany 
Paraformadehyde          Sigma-Aldrich, Munich, Germany 
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Formaldeyde 4%          Applichem, Darmstadt, Germany 
RotiClear            Roche, Mannheim, Germany 
Rat tail collagen-I          Sigma-Aldrich, Munich, Germany 
NP40             Roth, Karlsruhe, Germany 
Trypanblue            Sigma-Aldrich, Munich, Germany 
Agarose            Biozym, Oldendorf. Germany 
LB Agar            Roth, Karlsruhe, Germany 
LB medium           Roth, Karlsruhe, Germany 
Glycerin            Roth, Karlsruhe, Germany 
 
Antibodies 
An overview on antibodies used in current study is provided in Table 5. 
Table 5. Antibody list  
Target Species Company Cat.No. Dilutions 
YB-1_C-term Rabbit Eurogentec, EP085177 1:1000 (WB), 1:100 (ICH/IF)
YB-1_Royer Rabbit Eurogentec, EP081822 1:1000 (WB), 1:100 (ICH/IF)
DbpA Rabbit Eurogentec, EP052151 1:1000 (WB), 1:100 (ICH/IF)
GAPDH Rabbit Cell Signaling, 2118L 1:5000 (WB) 
β-actin Mouse Sigma, A1978 1:10000 (WB) 
Twist1 Rabbit Santa Cruz, sc-15393 1:1000 (WB), 1:50 (ICH/IF) 
E-cadherin Mouse BD Bioscience, 610181 1:1000 (WB), 1:100 (ICH/IF)
Snail Rabbit Abcam, ab85931 1:100 (ICH/IF) 
S100A4 Rabbit Abcam, ab27427 1:50 (ICH/IF) 
pSmad2 Rabbit Cell Signaling, 3101S 1:1000 (WB) 
ZO-1 Rabbit Abcam, ab59720 1:50 (ICH/IF) 
Rabbit IgG Goat Santa Cruz, sc-2301 1:10000 (WB) 
Mouse IgG Goat Santa Cruz, sc-2305 1:10000 (WB) 
Alexa Fluor 488 Goat Invitrogen, A-11001 1:200 (IF) 
Alexa Fluor 633 Goat Invitrogen, A-21071 1:200 (IF) 
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2.2 Buffers and solutions 
 
Cell lysis buffer (RIPA buffer). 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 % Nonidet P-40 
(NP40), 0.5 % sodium deoxycholate, 0.1 % SDS, Proteases Inhibitor Cocktail (Roche, Mannheim, 
Germany), Phosphatase Inhibitor Cocktail II, Roche, Mannheim, Germany.  
 
SDS-PAGE  
The composition of gels was as follows: 
 
Table 6. SDS-PAGE gels 
Separating gel 12% 10% 
Acrylamid   2.6 ml  2.25 ml
1.5 M Tris pH 8.8  1.6 ml 1.62 ml
ddH2O  2.2 ml 2.61 ml
SDS (10%)  66.7 µl 66.7 µl
TEMED   6.0 µl  6.0 µl
APS (10%)  40.0 µl 40.0 µl
Stacking gel:  
Acrylamid  0.3 ml
1M Tris pH 6.8  0.5 ml
ddH2O  1.1 ml
SDS (10%)  19.1 µl
TEMED  3.4 µl
APS (10%)  22.9 µl
 
10x Running buffer. 144 g Glycin, 30,34 g Tris (for electrophoresis), 100 ml 10% SDS (for 
electrophoresis); filled up to 1 L with ddH2O, pH 8.3. 
 
Transfer buffer. 750 ml ddH2O, 200 ml methanol, 50 ml NuPAGE Transfer Buffer (20x) 
(Invitrogen, Karlsruhe, Germany). 
 
10X TBS (Tris-buffered saline). 12.1 g Tris-base (Merck, Darmstadt, Germany), 87.66 g NaCl 
(Merck) dissolved in 800 ml ddH2O. pH adjusted to 7.6 with 1 M HCl; filled up with ddH2O to 1L. 
 
 - 40 - 
TBST. 100 ml of 10 x TBS and 10 ml of 10 % Tween20 solution (Bio-Rad Laboratories, Hercules, 
CA) adjusted with distilled water to 1 L. 
 
Blocking solutions. 5 g of non-fat milk or BSA dissolved in 100 ml TBST. 
 
Reducing buffer. 1M DTT. 154 mg dithiothreitol (DTT, Sigma) dissolved in 1 ml ddH2O; aliquots 
were kept at -20°C till use. 
 
5x Tris/Glycin loading buffer. 2.5 ml β-mercaptoethanol (12,5%), 2 g SDS (10%), 10 mg 
Brom-Phenoblue, 6 ml 1 M Tris HCl pH 6.8 (0.3 M), 200 µl 500 mM EDTA (5 mM), 10 ml 99% 
glycerin (50%) and 1.3 ml ddH2O. 
 
Stripping buffers 
Buffer 1. 62.5 mmol Tris/HCL (7.56 g), 2% SDS (20 g) for 1 L, pH was adjusted to 6.7; working 
solution as follows: 100 ml buffer, 80 µl β-mercaptoethanol. Membranes were incubated in working 
solution for 10-30 min at 60-70°C. Washed with TBST and blocked again for re-probing. 
Buffer 2. 0.2 M NaOH; procedure: membrane was washed for 5 min in ddH2O, 5 min in 0.2 M 
NaOH, again 5 min in ddH2O. Then, membranes were washed with TBST and blocked again prior 
antibody incubation. 
 
MOPS running buffer. Freshly prepared by diluting 25 ml of NuPAGE MOPS SDS Running 
Buffer (20 x) (Invitrogen GmbH) in 475 ml ddH2O.  
 
Fixation solution  
Buffer 1. 10% Formalin. Dilute 37% Formaldehyde 10 time. Do not store longer than 3 months. 
Buffer 2. Methacarn. 60% Methanol, 30% Chlorofrom and 10% glacial acetic acid. 
Buffer 3. 4 % paraformaldehyde (PFA). Add 4 g paraformaldehyde to 50 ml hot water, add 
NaOH drop wise under agitation until solution is clear, add 10 ml 10 x PBS, adjust pH 7.4 using 
phosphoric acid, add water to 100 ml end volume. Store in -80°C or use directly. 
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Permeabilization buffer. 0.3% Triton X-100 v/v in PBS pH 7.4. 
 
Antigen retrieval buffer 
Buffer 1: 10mM Na-Citrate Buffer. To prepare 1 L add 2.94 g Na-Citrate to dH2O and adjust to 
pH6.0 
Buffer 2: 1mM EDTA Buffer. To prepare 1 L add 0.372 g EDTA to dH2O and adjust to pH8.0 
 
Tween washing buffer. add 500 µl 10% Tween 20 solution to 49.5 ml PBS. This results in a final 
concentration of 0.1% v/v.  
 
Blocking buffer. 1 % BSA in PBS for immunofluorescence; 50% FCS and 0.1%BSA in PBS for 
immunohistochemistry. 
 
Protein ladder. See Blue plus2 pre-stained (Invitrogen, Karlsruhe, Germany) 
 
TCA solution. add20g TCA to 100 dH2O and store at 4°C 
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2.3 Cell culture and incubation protocols 
 
Rat mesangial cells were grown in RPMI 1640 medium supplemented with 10% FCS and 100 
IU/ml penicillin at 37°C in humidified air containing 5% CO2.  
 
Primary human mesangial cells (cc-2559, Lonza Group Ltd, Swizerland) were grown in 
Clonetics™ MsGM™ culture system (CC-3146, Lonza Group Ltd, Swizerland) containing 
Mesangial Cell Basal Medium 500ml supplemented with FBS25ml, GA-1000 0.5 ml, at 37°C in 
humidified 5% CO2 in air.  
 
Human embryonic kidney cells (HEK-293), human proximal tubular epithelial cell lines 
(HK-2 and HKC-8) were grown in DMEM/F12 medium supplemented with 10% FCS and 100 
U/ml penicillin at 37°C in humidified air containing 5% CO2. 
 
Primary hepatic stellate cells (HSCs) were isolated from livers of Wistar rats and cultured in 
DMEM medium supplemented with 4 mmol/L-glutamine, 10% FCS and 100 IU/ml penicillin. The 
first medium change was performed 24 hours after seeding. Cells were maintained at 37°C in 
humidified air containing 5% CO2. 
 
Mouse liver progenitor cells (LPC) were grown in Williams’E medium supplied with 2% FCS, 15 
ng/ml IGF-II, 10 ng/ml EGF and 5ug/ml ITS.  
 
Cytokine incubation 
As TGF-β and IL-13 exhibit cross reactivites between species (human, mouse and rat), human 
TGF-β (5 ng/ml) and IL-13 (50 ng/ml) were used to perform cytokine incubation studies. 50 ng/ml 
rat or human PDFG-BB were used to stimulate rat or human mesangial cells, respectively. Before 
stimulation, mesangial cells were growth-arrested with serum-free MCDB-Medium (Sigma) for 24 
hours. FCS was reduced to 0.5% for starvation overnight of primary HSCs and to 0% for other cell 
lines before cytokine incubation.  
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2.4 Protein work 
 
Protein lysates of cultured cells 
Cell lines and hepatocytes were washed twice with ice cold PBS and lysed with 150 µl ice-cold 
RIPA buffer in 6 well culture plates. Cells were scraped with a rubber policeman and collected in 
1.5 ml tubes. The solution was kept in ice for 45 min and centrifuged for 15 min at 13.000 rpm, 4°C. 
The supernatant was collected and protein concentrations were determined using the Bio-Rad 
protein assay. For SDS-PAGE, 10-20 µg/well were supplemented with reducing buffer and loaded 
onto the gels for electrophoresis.  
 
Protein concentration measurement 
Protein concentrations were determined using the DC Protein Assay (Bio-Rad Laboratories) that is 
based on the Lowry assay. Each probe was quantified as triplicates in a micro-titer plate and 
measured. The absorbance was quantified at 690 nm using a spectrophotometer (Tecan). Protein 
concentrations were calculated as averages and related to the protein standard curve (prepared by a 
BSA dilution series) and a blank value obtained with RIPA buffer only. 
 
Western blot 
For Western bloting 10-20 µg of proteins were pipetted into a 1.5 ml tube. 5 µl of NuPage LDS 
Sample Buffer (4x) (Invitrogen GmbH) and 1 µl of 1 M DTT were added. Samples were adjusted to 
20 µl with sterile water. After 10 min of incubation at 95°C the samples were briefly centrifuged at 
14.000 rpm and loaded onto SDS-PAGE gels from Invitrogen. When using self-made gels 
(Tris/Glycin system), protein samples were added to loading buffer containing β-mercaptoethanol. 
 
SDS-PAGE SDS-polyacrylamide gel electrophoresis under denaturing conditions. NuPAGE 4-12 
% Bis-Tris gel (Invitrogen GmbH) and MOPS buffer were used as standard protocol. 
Electrophoresis was carried out in an XCell II Mini Cell apparatus (Invitrogen GmbH) for about 1 
hour at constant voltage of 150 V. Alternative standard protocol: Self-made gels were prepared 
(10-12 %) and ran in a Bio-Rad chamber for 2 h at constant voltage of 100 V in Laemmli running 
buffer. 
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Protein transfer on membranes 
Protein transfer onto nitrocellulose membranes was performed using an XCell II blotting apparatus 
with an XCell II Blot Module (Invitrogen GmbH). Chromatography paper (Whatman, Maidstone, 
England) and nitrocellulose membrane sheets (0.45 micron, Pierce, Rockford, IL) were used to 
prepare a gel membrane sandwich. Blotting pads and the gel membrane sandwich were placed in 
the XCell II Blot module according to the manufacturer’s instructions with transfer buffer. Blotting 
was performed for 1.5 h at constant currency of 250 mA. 
 
Immunodetection of proteins 
The blotted nitrocellulose membrane was incubated with Ponceau Red solution to determine equal 
loading and to allow cutting of membranes. After washing of the membranes with TBST, 
membranes were blocked for 1 h at room temperature followed by incubation with 1st antibody 
overnight at 4°C. The membranes were washed 3 times in TBST buffer and incubated with the 2nd 
antibody conjugated with peroxidase for 1 h at room temperature, then washed 4 times (for 5 min) 
in TBST. To detect protein on the membranes ECL solution was added. Chemiluminescence was 
detected using a Fujifilm LAS 1000 image detection system or the Chemi-Smart system from 
INTAS. 
 
Precipitation of secreted proteins (TCA) 
750 ul cell culture medium was added 1:1 to the 20% TCA solution, then mixed and stored in -20°C 
overnight. Next day, the samples were thawed in ice and centrifuged at 13.000 rpm for 30 min in 
4°C. Discard the complete supernatant and re-suspended the pallet with 1ml ice-cold 70% Ethanol, 
then centrifuged again at 13.000 rpm for 30 min in 4°C and discard the supernatant. When the pellet 
was dry, dissolved it in ddH2O for immediately using or stored it at -80°C. 
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2.5 Immunohistochemistry and immunofluorescence staining 
 
Tissue fixation, embedding and sectioning 
Tissue samples were fixed for the indicated times (depends on the sample size) with either 10% 
formalin or methacarn, then dehydrated through a graded ethanol series and embedded with paraffin 
wax and cast into blocks. Paraffin blocks were cut into 4 um sections and mouted on 
poly-L-lysine-coated glass slides for further staining processing. 
 
Cells fixation for immunofluorescence 
Cells were washed twice with PBS and fixed in 4% PFA/PBS for 10 minutes, followed by 
permeabilization with permabilization buffer for 5 min and fixed a second time with 2% PFA/PBS 
for 5 min and washed 3 times in PBS. 
 
Immunohistochemistry and immunofluorescence 
Immunohistochemistry and immunofluorescence were performed using following protocols: 
Paraffin-embedded tissue sections were deparaffinized in RotiClear and rehydrated in graded 
ethanol. Endogenous peroxidase and nonspecific binding were blocked by incubation with blocking 
solutions (Dako). The sections were incubated overnight at 4 °C with the primary antibody diluted 
in PBS plus 1% BSA (Sigma). Following day, after 3 times washed in PBS, the sections were 
incubated with peroxidase labeled second antibody (Dako) for 1 hour at room temperature. Staining 
were developed with diaminobenzidine (DAB). For formalin fixed, paraffin-embedded biopsy 
tissue sections, an additional antigen retrieval step was necessary after the rehydration, that to heat 
the sections by microwave 600W for 10 min within 10 mM sodium citrate (pH 6.0) or 1 mM EDTA 
(pH 8.0) buffer. Negative controls for the immunohistochemical procedures consisted of 
substitution of the primary antibody with nonimmune rabbit IgG (Dako). For immunofluorescence, 
fluorescencedye-labeled second antibodies were used instead of peroxidase labeled second 
antibody. 
 
Phase contrast and fluorescent microscopy 
Phase contrast and conventional epi-fluorescence images were obtained with the Leica IPB 
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microscope equipped with a Leica DC500 camera (Leica Microsystems, Wetzlar, Germany). For 
conventional epi-fluorescent images, excitation was performed with an EQB 100 isolated 
fluorescent lamp. Image acquisition was done with Leica IM50 software. 
 
Confocal microscopy 
Confocal images were obtained by using a Leica laser scanning spectral confocal microscope, DM 
IRE2, with an HCX PL Apo 40x/1.32 numeric aperture oil objective (Leica Microsystems, Wetzlar, 
Germany). Excitation was performed with an argon laser emitting at 488 nm, a krypton laser 
emitting at 568 nm, and a helium/neon laser emitting at 633 nm. Images were acquired with a TCS 
SP2 scanner and Leica Confocal software, version 2.5 (Leica Microsystems). 
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2.6 mRNA isolation, cDNA synthesis and real- time PCR 
 
RNA isolation  
RNA isolation was performed using RNeasy kit (Qiagen, Hilden, Germany) following the manual. 
Cells growing in 6 well plates were lysed with 350 μl RLT buffer, homogenized and adjusted with 
ethanol for proper binding conditions. Samples were pipetted into a spin column for isolation. After 
centrifugation, followed with 3 time wash; the RNA was eluted with water in a final volume of 40 
µl. RNA concentrations were determined using a spectrophotometer. The integrity of the isolated 
RNA was examined by formaldehyde agarose gel electrophoresis. 
 
Reverse transcription 
Reverse transcription reaction to cDNA was performed using Omninscript Reverse Transcription 
Kit (Qiagen) according to the manual. 1 μg total RNA was reverse transcribed into 20 μl cDNA and 
used for quantitative real-time PCR and conventional PCR. RT reaction was allowed to proceed at 
42°C for 30 min followed by a denaturation step at 94°C for 5 min. For qRT-PCR, samples were 
diluted 1:10 or 1:100 with ddH2O, respectively. 
 
Quantitative real time PCR 
Quantitative real-time RT-PCR (qRT-PCR) was performed with the sequence detection system 
from Stratagene, Mx3005P using TaqMan Universal PCR Master Mix, No AmpErase UNG (Part 
No. 4324018) and the following Gene Expression Assays: Rat DbpA (Rn00519737_m1), 18S 
ribosomal RNA (Hs99999901_s1). All reagents were purchased from Applied Biosystems. Samples 
were run in triplicate by using an ABI Prism 7700 sequence detector (Applied Biosystems, 
Weiterstadt, Germany). Levels of gene expression were determined by the comparative CT method 
for relative quantfication of gene expression. Relative quantification relates the PCR signal of the 
target transcript in a treatment group to that of another sample such as an untreated control. Real 
time PCR conditions for analyzed genes: 1 Denaturation 95°C 10 min; 2 Denaturation 95 °C 30 sec; 
3 Annealing and amplification 60°C 30 sec; 4 Cycle step 2-3 for 39 times 
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2.7  DNA work and gene cloning 
 
Design primers for target DNA fragments. Add restriction enzymes target sequence to 
5’terminus of forward primers (KpnI) and reverse primers (XhoI) respectively. Primers were 
designed using online primer designing tool: Primer3. Table 7 shows the primers that have been 
used for current study.  
 
Amplify target DNA fregments with PCR following the protocol from manufacturer, peqGOLD 
Pwo DNA polymerase from PEQLAB. Run 1% agarose gel with PCR products, check the DNA 
size and cut the gels with target DNA fragments. Purify the gel extractions with QIAquick Gel 
Extraction kit from QIAGEN). 
Digest insert and vector with restriction enzymes following the protocol from manufacturer, 
FastDigest® enzymes from Fermentas. Purify the DNA from enzymatic reaction with QIAquick 
Gel Extraction kit from QIAGEN. 
Ligation of vector plasmid and insert performed using T4 DNA ligase from Roche, following the 
protocol from manufacturer.  
Table 7. Primer list 
Name F/R Sequence  Company 
DbpA_P-1633 F GGT ACC GGT ACC ATG GTC AGT CCT CAC CAG AA Invitrogen 
DbpA_P-1096 F GGT ACC GGT ACC TGT TTG AGG GAA CAG GCA AT Invitrogen 
DbpA_P-964 F GGT ACC GGT ACC AAA CCG ACT CTG GGA CAT TG Invitrogen 
DbpA_P-668 F GGT ACC GGT ACC AGA GGC AAC TGG AGC AGA AG Invitrogen 
DbpA_P-527 F GGT ACC GGT ACC CAA TTT CCT CAT CTG CGT GTT Invitrogen 
DbpA_P-173 F GGT ACC GGT ACC GCT TTC CTT GGT TCT GCA AC Invitrogen 
DbpA_P+41 R CTC GAG CTC GAG CGA TCT TAC TGC CCC AAA AA Invitrogen 
 
YB-1_P-1393 F GGT ACC GGT ACC TGG TCG GCC AAG CTT ATA TT Invitrogen 
YB-1_P-1060 F GGT ACC GGT ACC TCT CAC TCT TCC CCT CAG GA Invitrogen 
YB-1_P-513 F GGT ACC GGT ACC GCC TGG TAA AAC GGA TCA GA Invitrogen 
YB-1_P-230 F GGT ACC GGT ACC GGC TAA GGC GTC TTC GAG Invitrogen 
YB-1_P-144 F GGT ACC GGT ACC GAG ACA CAA CCC TGA ACG TG Invitrogen 
YB-1_P-27 F GGT ACC GGT ACC TAG TTC CGG TCT CTA TGG CG Invitrogen 
YB-1_P+283 R CTC GAG CTC GAG CCG GGG TGT GAT GGT AAC TA Invitrogen 
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Transformation. Ligated plasmids were first mixed with baterial cells and incubated in ice for 30 
min. After a heat shock at 42oC for 45 seconds, return it back to ice for 5 min. Then incubate with 
LB medium in 37 °C for 1 hour. Selection of the taget bacteria with recombinant plasmid was 
performed spreading the solution onto an LB agar plate containing the designed resistant antibiotic, 
e.g. Ampicillin.  
Culture selected bacteria clones for Miniprep, following the protocol from manufacturer, 
Miniprep kit from QIAGEN or Fermentas. 
Digest the DNA products from Miniprep, run 1% agarose gel and check the DNA size. When the 
size is correct, send it to sequence.  
Maxiprep. When DNA sequence confirmed the cloning was successful, Maxiprep was performed 
to amplify the plasmids, following the protocol from manufacturer (QIAGEN or Fermentas). The 
products were used directly for cell transfection or stored at -20 °C for short period or at -80 °C for 
longer time. 
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2.8 Luciferase assay 
 
Transient transfection and stimulation 
Rat mesangial cells (150,000/well) were seeded in 6-well plate and let them grow overnight to 
50-60% confluence. The following day, cells were transfected with pGL4.10-Basic and other 
construted plasmids (2 µg of each plasmid/well) in triplicate, accompanied with internal control 
pGL4.74 (0.1 µg/well) using FuGene (Roche) or Tfx50 (Promega). The cells were incubated at 
37℃, 5% CO2 for 24 hours, then were growth-arrested with serum free MCDB-Medium (Sigma) 
for another 24 hours before stimulation. Luciferase assay test was performed after challenge the 
cells with 50 ng/ml rat PDGF-BB or 5 ng/ml TGF-β for 24 hours. 
 
Luciferase assay test & analysis 
After removing the growth medium and washing the wells with PBS, luciferase assay test was 
performed according to the manufactur’s protocol (Promega). Lysate buffer, PLB, was added to 
each well and incubated at room temperature for ten minutes with agitation. Then the lysate samples 
were transferred in to a polypropylene tube for testing. Luciferase substract was added and read in a 
luminometer (Tecan). The reading corresponds to firefly luciferase activity. There after Stop & Glo 
reagent was added and the reading was taken as the renilla activity. The luciferase activity of each 
well was normalized by the renilla value using the formula; Ln = F/R (Ln: normalised luciferase 
activity; F: Firefly luciferase activity reading and R: Renilla activity reading). Transcriptional 
activity of the control, pGL4.10-Basic, was used to further standardize Ln using the formula; RLU 
= Ln/pGL4.10-basic (RLU: relative luciferase unit).   
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2.9 Human biopsies and animal studies 
 
Human biopsies 
Human kidney biopsy samples encompassed diagnosis IgA nephropathy (n=8), lupus nephritis 
type IV (n=5) and interstitial nephritis (n=5). Human liver biopsy samples encompassed diagnosis 
HBV infectd hepatitis (n=22), NASH (n=3) and hepatocellular carcinoma (n=5). Healthy control 
tissues were sampled from patients undergoing nephrectomy or hepatectomy due to cancer diseases. 
Macroscopically unaffected tissue was embedded and analyzed. The study protocol involving 
human samples was approved by the local ethics committees. Patients provided written informed 
consent. The study protocol adhered to the ethical guidelines of the 1975 declaration of Helsinki. 
 
Mesangioproliferative anti-Thy1.1 nephritis model 
Anti-Thy1.1 nephritis was induced in 28 male Wistar rats (Charles River Wiga GmbH; 160 to 180 g) 
by intravenous injection of 1 mg/kg monoclonal anti-Thy1.1 antibody (clone OX-7; European 
Collection of Animal Cell Cultures, Salisbury, UK) as described (Floege, Ostendorf et al. 1999). 
Control and treated animals were sacrificed after 4 hours and days 4, 7, 9, 14, 21 and 28 after 
disease induction (n=4 at each time point). Tissues were used for protein extracts as well as fixed in 
Methacarn solution, embedded in paraffin, and sectioned for immunohistochemistry staining.  
 
PDGF-BB infusion 
Infusion of PDGF-BB in vivo was performed as described earlier (Floege, Eng et al. 1993). Briefly, 
five normal male Wistar rats (Simonson, Gilroy, CA) with weights between 180 to 220 g received a 
7-d intravenous infusion of 40 ug/d PDGF-BB, and five rats received a vehicle. Infusion was 
performed continuously through a catheter in the left internal jugular vein with micro-osmotic 
pumps. Renal biopsies were obtained from each rat at day 4 and day 7. 
 
Treatment of nephritic rats with PDGF-B–specific aptamers 
Anti-Thy1.1 mesangioproliferative GN was induced in male Wistar rats as described above. Rats 
received daily two intravenous injections of 0.33 mg of PDGF-B specific aptamers or control 
vehicle. starting at day 3 after the onset of anti-Thy1.1 glomerulonephritis (GN) as described 
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previously (van Roeyen, Eitner et al. 2005; van Roeyen, Eitner et al. 2008). Necropsies were 
performed in all rats at day 6.  
 
Treatment of nephritic rats with MEK inhibitor U0126 
Anti-Thy1.1 mesangioproliferative GN was induced in male Wistar rats as described above. Rats 
received twice a day intraperitoneal injections of 20 or 200 mg/kg of U0126 dissolved in DMSO or 
control vehicle, starting at day 3 after the induction of anti-Thy1.1 glomerulonephritis (GN) as 
described previously (van Roeyen, Eitner et al. 2005; van Roeyen, Eitner et al. 2008). Necropsies 
were performed in all rats at day 6. The animals received the last dose of U0126 1h before being 
killed.  
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3 Results  
 
3.1 DbpA protein expression 
 
Two isoforms of DbpA/ZONAB protein exist in humans that differ from one another by a 69 amino 
acids (aa) long alternative domain localized within the protein C-terminus (Figure 7A) (Kudo, 
Mattei et al. 1995; Balda and Matter 2000).  The longer isoform is denoted DbpA-a or ZONAB-B 
and encompasses 372 aa (NP_003642.3), while the shorter isoform, DbpA-b/ZONAB-A consists of 
303 aa and lacks the alternative domain (NP_001138898.1). Given the high conservation of the 
CSD but very low homology within the N-terminal domains, a peptide-derived polyclonal antibody 
(Ab) was generated that specifically recognizes an epitope within the N-terminus of human DbpA 
(Figure 7A). With this antibody, both isoforms may be detected by Western blotting and 
distinguished due to size differences.  
 
DbpA protein expression was first assessed by immunoblotting of whole cell lysates from different 
cell types, including human monocytic leukemia cell line (THP-1), human proximal tubular 
epithelial cell line HK-2 and HKC-8, an immortalized rat mesangial cell line (rMC), human primary 
mesangial cells (p hMC), human embryonic kidney cells (HEK-293), a mouse liver progenitor cell 
line (LPC), human cholangiocytic cell line (MMNK-1), human hepatocyte cell line (AML-12) and 
rat hepatic stellate cell line (CFSC) . Differences in expression patterns for DbpA are shown in 
Figure 7B. Three distinct bands were detected, that correspond to relative MW of ~55, ~50 and ~44 
kDa. The two bands at ~55 and ~50 kDa correspond to the reported sizes of DbpA isoforms 
DbpA_a (~55 kDa) and DbpA_b (~50 kDa) (Kudo, Mattei et al. 1995; Balda, Garrett et al. 2003). 
The ~44 kDa band has not yet been reported and may be derived by proteolysis or represent an 
unreported isoform. Specificity of the Ab is confirmed by testing pre-immune serum and by 
omission of the primary Ab.  
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Figure 7. DbpA protein expression in different cell lines. (A) Structural composition of DbpA protein isoforms with 
alternative domain (AD). DbpA specific antibody (Ab) recognizes an epitope within the N-terminal domain (B) By 
Western-blot analysis DbpA protein expression of cell lysates from different kidney and liver cell lines: human 
monocytic cell line (THP-1), human proximal tubular epithelial cells HK-2 and HKC-8, rat mesangial cell line (rMC), 
human primary mesangial cells (p hMC), human embryonic kidney cells line (HEK-293), mouse liver progenitor cell 
line (LPC), human cholangiocytic cell line (MMNK-1), human hepatocytic cell line (AML-12) and rat hepatic 
stellate cells (CFSC) . Three major bands at ~55, ~50 and ~44 kDa are detected and denoted as DbpA_1, _2 and _3 
respectively.  
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3.2 DbpA expression in mesangioproliferative glomerulonephritis (GN) 
 
Mesangial cell (MC) activation and proliferation are prominent features of mesangioproliferative 
glomerular diseases, in which PDGF-B has been established as a potent mitogen (Floege, Ostendorf 
et al. 1999; Floege, Eitner et al. 2008). Among the known downstream targets of PDGF-B signaling, 
cold-shock protein DbpB/YB-1 has been identified previously in mesangioproliferative glomerular 
disease (van Roeyen, Eitner et al. 2005). Given that DbpA may play a role in cell proliferation and 
considering the structural and functional similarities between DbpA and DbpB/YB-1 we 
hypothesized that DbpA may also be a downstream target of PDGF-B signaling. 
 
3.2.1 Elevated DbpA expression in human IgA and lupus (IV) nephritis  
 
IgA nephritis and lupus nephritis (type IV) are often accompanied by MC proliferation and matrix 
accumulation. Within the glomerulus DbpA protein expression was first assessed in human kidney 
biopsy samples from IgA and lupus (IV) nephritis patients. Compared to healthy controls a strong 
induction of DbpA protein expression within the mesangial compartment was detected by 
immunohistochemistry (Figure 8). The localization of DbpA was mainly within the cytoplasm.  
 
Figure 8. Expression of DbpA in IgA and lupus nephritis patients. By immunohistochemistry, DbpA was hardly 
detected in healthy controls (a, b). In contrast, DbpA protein was detected within the mesangial compartment of 
glomeruli from IgA (c, d) and lupus (e, f) nephritis patients.  
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The analysis was extended to patients suffering from interstitial nephritis (IN). Expression of DbpA 
was berely detectable within the glomeruli, and in this respect not distinguishable from healthy 
controls (Figure 9). However tubules and tubulointerstitial cells were immunopositive for DbpA. 
Notably the staining pattern included unclear and cytoplasmic localization and did not adhere to cell 
boundaries. These observations provided the first clue that DbpA may be involved in the 
proliferative mesangial cell response in mesangioproliferative glomerulonephritis.  
Figure 9. Expression of DbpA in interstitial nephritis patients. DbpA expression was hardly detected in the 
glomeruli of healthy controls (a) and patients suffering from interstitial nephritis (c). Positive DbpA signal was 
observed in some cells localized within the interstium of healthy kidney tissue (arrow) within the nuclear compartment 
(b). Strong induction of DbpA expression was seen within infiltrating cells in interstitial nephritis patients (d).  
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3.2.2 DbpA expression in the Anti-Thy1.1 mesangioproliferative GN model 
 
The anti-Thy1.1 nephritis model is an antibody-mediated, complement-dependent rodent nephritis 
model that has ben established as a model for human mesangioproliferative diseases. In healthy rat 
kidneys DbpA protein expression was hardly detected by immunohistochemistry within the 
glomeruli. Please note, that smooth muscle cells within blood vessels were immunopositive, 
yielding an internal positive control (Figure 10, a and b). Induction of the anti-Thy1.1 GN resulted 
in a marked change of DbpA protein expression within the glomeruli. Immunohistochemistry was 
performed on tissue samples collected 4 hours, 4, 7 and 21 days after disease induction. In the 
course of disease, cytoplasmic DbpA protein abundance coincided with mesangial cell 
activation/proliferation, that reached a plateau at day 7 (Figure 10, g and h) and returned to 
“background” after 3 weeks (Figure 10, i and j). The localization of DbpA protein remained 
predominantly cytoplasmic and was prominent within the mesangial compartment (Figure 10, h).  
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Figure 10. Expression of DbpA protein in healthy rat kidney and following induction of anti-Thy1.1 
mesangioproliferative glomerulonephritis. DbpA protein was identified by immunohistochemistry in kidney tissue 
from healthy rats (a, b) and in the time course of anti-Thy1.1 nephritis (4 hours: c, d; day 4: e, f; day 7: g, h; day 21: i, j). 
Whereas no DbpA protein was detected in the glomeruli of healthy rats significant DbpA expression within the 
cytoplasm of mesangial cells was observed following induction of anti-Thy1.1 nephritis from day 4 on, peaking at day 7 
and returning to ’background level’ after three weeks. (a. c. e. g and i with 100x magnification; b, d, f, h and j with 400x 
magnification) 
 
 - 59 - 
Besides immunohistochemistry we performed Western blot analyses of glomerular lysates from 
animals without and with anti-Thy1.1 nephritis. Here a marked (3.5-fold) up-regulation of DbpA 
protein expression was apparent within 4 days that peaked at day 7 and subsequently returned to 
“background level” within two weeks (Figure 11). Of note there was only one form of DbpA 
protein detected with relative MW of ~44 kDa. 
 
Figure 11. Western blot analysis of DbpA protein expression in the course of anti-Thy1.1 nephritis. Only band 
corresponding to ~ 44 kDa was detected by Western blot. Quantitative analyses reveal ~ 3.5-fold up-regulation of DbpA 
protein expression that peaks at day 7 and subsequently returns to background levels. 
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3.2.3 In vivo infusion of PDGF-BB results in stimulated DbpA protein expression 
 
The potent role of PDGF-B in mesangioproliferative glomerular disease is well established, and a 
strong induction of PDGF-B expression in the anti-Thy1.1 model has been described (Floege, 
Ostendorf et al. 1999). In order to address the question whether cytokine PDGF-B may induce 
DbpA expression in mesangioproliferative glomerular disease animals were continuously infused 
with PDGF-BB (40 ug of PDGF-BB/d versus vehicle alone). By immunohistochemistry a marked 
cytoplasmic expression of DbpA within the mesangial compartment of glomeruli was apparent in 
the PDGF-BB receiving animals at both examined time points, days 4 and 7. For vehicle-infused 
animals no DbpA positive staining was observed (Figure 12). 
Figure 12. Renal expression of DbpA following in vivo infusion of PDGF-BB. Immunohistochemistry for DbpA was 
performed with kidney biopsies from rats that were infused with vehicle for 7 days (control) or with PDGF-BB for 4 
and 7 days respectively. Whereas control tissue was immunonegative for DbpA in the glomeruli DbpA protein’ 
induction was apparent within the mesangium of PDGF-BB infused rats, on days 4 and 7.  
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3.2.4 PDGF-B blockade inhibits DbpA expression in mesangioproliferative GN  
 
To corroborate PDGF-BB as an endogenous upstream inducer of DbpA expression in vivo, in 
blockade of extracellular PDGF-B activities was sought via application of specific neutralizing 
aptamers in diseased animals. Anti-Thy1.1 nephritis was induced and rats subsequently received 
twice daily injections of specific PDGF-B aptamers (0.33 mg PDGF-B aptamers versus vehicle 
alone) from days 3 to 6 (van Roeyen, Eitner et al. 2005) (Figure 13A). Application of PDGF-B 
aptamer antagonists abrogated DbpA protein expression when compared to vehicle-infused diseased 
animals (Figure 13B). Additionally, DbpA expression closely coincided with mesangial cell 
activation and proliferation. Taken together these findings indicate that DbpA is a downstream 
target of PDGF-B.  
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Figure 13. In vivo treatment of anti-Thy1.1 nephritis rats with PDGF-B specific aptamers abrogates DbpA 
up-regulation. (A) Scheme on experimental protocol. Anti-Thy1.1 nephritis was induced in animals thereafter 
receiving PDGF-B aptamers or vehicle alone twice daily from days 3 to 6. (B) Immunohistochemistry reveals decreased 
DbpA expression in PDGF-B aptamer treated rats (d, e and f) compared to vehicle infused animals (a, b and c). 
Representative results are depicted that were obtained with three different animals in each group.  
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3.2.5 MEK inhibitor U0126 represses DbpA expression in Anti-Thy1.1 model 
 
Among downstream signaling events activated by PDGF-B the MAPK/ERK pathway seems to be 
of fundamental important for mesangial cell activation and proliferation. In order to test this 
hypothesis blockade of MAPK/ERK signaling activities via application of MEK inhibitor U0126 in 
diseased animals was performed. Anti-Thy1.1 nephritis was induced as previously described and 
the rats subsequently received twice daily injections of U0126 (20 or 200 mg/kg versus vehicle 
alone) from days 3 to 6 (scheme depicted in Figure 14A). Tissue was processed as described (van 
Roeyen, Eitner et al. 2005). Following application of U0126 DbpA protein expression was reduced 
compared to vehicle-infused diseased animals (Figure 14B). 
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Figure 14. In vivo treatment of anti-Thy1.1 nephritis rats with MEK inhibitor U0126 leads to decreased DbpA 
up-regulation. (A) Scheme on experimental protocol. Anti-Thy1.1 nephritis was induced in animals, thereafter 
were injected U0126 or vehicle alone twice daily from days 3 to 6. (B) Immunohistochemistry reveals decreased DbpA 
expression in U0126 treated rats (c, d, e and f) comparing to vehicle treated (a and b). A concentration-dependent effect 
becomes apparent. Representative results are depicted that were obtained with three different animals in each group.  
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3.2.6 PDGF-BB regulates DbpA expression in mesangial cells in vitro 
 
Given the above in vivo results we next set out to test whether DbpA is a downstream target of 
PDGF-B signaling in mesangial cells in vitro. Following incubation of primary human mesangial 
cell cultures with PDGF-BB at 50ng/ml for 24 hours morphological changes and increased cell 
proliferation rates were seen (see Figure 15).  
 
 
Figure 15. Morphological changes of primary human mesangial cells following PDGF-BB stimulation. Following 
PDGF-BB stimulation (50ng/ml) changes of mesangial cell morphology and increased cell numbers were apparent 
within 24 hours.  
 
Immunofluorescence staining for DbpA showed that its expression was increased and the protein 
predominantly accumulated within the cytoplasm (see Figure 16). These results are in accord with 
the observations found by immunohistochemistry. 
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Figure 16. DbpA accumulates within the cytoplasm of rat mesangial cells following incubation with PDGF-BB. 
Cells incubated with vehicle or PDGF-BB (50ng/ml) for 24 hours reveal a cytoplasmic accumulatetion of DbpA 
protein.  
 
Western blot analysis performed with cell lysates from primary human mesangial cells incubated 
with PDGF-BB or vehicle reveals a ~1.7 fold induction of DbpA protein expression. Notably, two 
isoforms were detected of molecule sizes of ~ 44 and ~ 55 kDa (Figure 17).  
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Figure 17. Western blot analysis of DbpA protein expression in PDGF-BB challenged primary human mesangial 
cells. Quantification of band intensities reveals ~1.5 fold induction of DbpA protein expression (~44 kDa) 24 hours 
following incubation with human PDGF-BB (50 ng/ml).  
 
In a well characterised rat mesangial cell line (rMC) incubation with PDGF-BB was performed for 
different time periods (1, 2, 8, 24 and 48 hours). DbpA protein and mRNA levels were determined 
by Western blot and real-time PCR respectively. A significant 2.5-fold induction of DbpA protein 
(~ 44 kDa) expression was detected following PDGF-BB stimulation for 24 hours (Figure 18A). 
DbpA transcripts were 3.5-fold more abundant following 48 hours of PDGF-BB incubation (Figure 
18B).  
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Figure 18. DbpA protein and transcripts are up-regulated following PDGF-BB stimulation of rat mesangial cells. 
(A) Western blot analysis of DbpA protein expression in rat mesangial cells challenged with rat PDGF-BB for the 
indicated time periods. A 2.5-fold induction of DbpA protein (~ 44 kDa) was detected after PDGF-BB stimulation for 
24 hours. (B) Real-time PCR analysis for DbpA transcripts reveals 3.5-fold up-regulation after 48 hours of PDGF-BB 
incubation.  
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3.2.7 PDGF-B stimulates DbpA secretion in rat mesangial cells 
 
We previously identified DbpA/YB-1 as a chemoattractant that is secreted by rat mesangial cells 
(Frye, Halfter et al. 2009; Rauen, Raffetseder et al. 2009). Here we tested the hypothesis that DbpA 
may also be secreted following PDGF-BB incubation. Western-blot analysis of conditioned cell 
culture medium precipitated by trichloroacetic acid (TCA) revealed that DbpA was detected 
extracellularly with prominent size of 50 kDa (Figure 19A). DbpA abundance in the medium 
elevated following PDGF-B stimulation in a time-dependent as well as concentration-dependent 
manner (Figures 19B and 19C). 
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Figure 19. PDGF-B stimulates DbpA extracellular secretion. (A) Western-blot analysis for DbpA expression in 
conditioned cell culture medium from rat mesangial cells and cell lysate. DbpA with relative MW of 50 kDa was 
detected within the supernatant, while a 44 kDa protein was detected in cell lysates. (B) Concentration-dependent 
release of DbpA from mesangial cells following PDGF-BB stimulation. Western blot analysis of DbpA protein in 
conditioned culture medium of rat mesangial cells challenged with PDGF-BB for 24 hours. Concentration-dependent 
up-regulation of DbpA (~ 50 kDa) is seen (C) Western blot analysis of DbpA protein abundance in the conditioned 
medium of rat mesangial cells stimulated with a fixed concentration of PDGF-BB (50 ng/ml) for the indicated time 
periods. A time-dependent up-regulation of DbpA protein (~ 50 kDa) was apparent after at least PDGF-BB stimulation. 
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3.3 Expression and regulation of CSP in inflammatory liver diseases 
 
Chronic inflammatory liver diseases may progress to fibrotic and cirrhotic damages of the liver 
structure, and concomitantly increase the risk for malignant transformation of resident liver cells 
with advent of hepatocellular and cholangiocellular carcinomas. A correlation of elevated DbpA 
and DbpB/YB-1 protein expression levels with advanced stages of hepatocellular carcinoma has 
been reported (Yasen, Kajino et al. 2005). However, little is known about roles that CSP play in 
chronic inflammatory liver diseases. From in vitro studies we know that DbpB/YB-1 activates 
Smad7 gene expression in hepatic stellate cells (HSC) and thereby attenuates the pro-fibrogenic 
effects of TGF-β (Dooley, Said et al. 2006). In vivo studies confirmed that DbpB/YB-1 has the 
potential to act protectively in experimental models of liver fibrosis and cirrhosis (Inagaki, Kushida 
et al. 2005).  
 
3.3.1 DbpA and DbpB/YB-1 expression in HBV-infected cirrhotic livers 
 
Around 80% of hepatocellular carcinomas (HCC) derive from liver fibrosis and cirrhosis, mostly 
related to viral hepatitis B and C infections (Trevisani, Cantarini et al. 2008). Given that DbpA and 
DbpB/YB-1 are involved in hepatocarcinogenesis, we first investigated the expression levels of 
these two proteins in HBV-infected cirrhotic patients. By immunohistochemistry a strong 
up-regulation of both DbpA and DbpB/YB-1 proteins in HBV infected chronic liver diseases 
comparing to the healthy liver tissues was apparent, as shown in Figure 20.  
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Figure 20. DbpA and DbpB/YB-1 protein expression in HBV infected cirrhotic livers. DbpA and DbpB/YB-1 
proteins were investigated by immunohistochemistry in healthy liver tissue (a, c) and in liver tissue from 
HBV-assosiated cirrhosis patients (b, d).  
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3.3.2 Distribution of DbpA and DbpB/YB-1 in cirrhotic liver tissue 
 
Both DbpA and DbpB/YB-1 were found to be over-expressed in cirrhotic liver tissue. The 
expression patterns however differed from each other. DbpA positive cells were mainly localized 
within the sinusoidal compartment. By immunofluorenscence co-staining with cell-type specific 
markers CD68 and α-SMA, DbpA positive cells were identified as activated macrophages and 
activated hepatic stellate cells (HSCs) (Figure 21 and 22). In contrast, DbpB/YB-1 immunopositive 
cells were mainly hepatic epithelial cells (e.g. hepatocytes, cholangial cells, reactive ductular cells 
and hepatic progenitor cells) as assessed by morphology and phenotypic appearance (Figure 23).  
 
Figure 21. DbpA and CD68 co-expression of cells. By immunofluorescence DbpA (green) and CD68 (red) 
co-staining of cells (in the overlay appearing as yellow) was visualized predominantly within the sinusoidal 
compartment of cirrhotic liver tissue. 
 - 74 - 
 
Figure 22. DbpA and α-SMA co-expression of cells. By immunofluorenscence of DbpA (green) and α-SMA (red) 
co-localization (overlay yellow) was identified within the sinusoidal compartment. 
 
Figure 23. Distribution of DbpB/YB-1 staining within cirrhotic liver tissue. Immunohistochemistry combined with 
phenotype analysis indicates that DbpB/YB-1 positive cells are mainly intermediated hepatocyte-like cells (a), 
hepatocytes (arrows, b), hepatic progenitor cells (arrow heads, c ) and bile ductular cells (arrow, c ). 
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3.3.3 DbpA is up-regulated in the early phases of hepatic fibrogenesis 
 
Given that DbpA up-regulation predominantly occurs in activated macrophages and activated 
hepatic stellate cells (HSCs), it may be involved in the fibrogenesis process of inflammatory liver 
diseases. As shown in Figure 24 DbpA protein expression is up-regulated in cells surrounding and 
constituting fibrotic tissue (triangles) from cirrhosis livers. However, at the later stages of fibrosis 
with scar tissue being formed, DbpA protein expression may be hardly detected, as indicated by 
stars within Figure 24. This distribution indicates that DbpA may be involved in the orchestration of 
the early phases of hepatic fibrosis.  
  
Figure 24. DbpA protein expression in hepatic fibrotic tissue. By immunohistochemisty DbpA was detected in 
cirrhosis samples, its protein level was found to be strongly up-regulated in active fibrotic areas (triangle). However, 
DbpA positive cells were scarcely detected in scar tissue (star).  
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3.3.4 DbpB/YB-1 expression correlates with liver regeneraton and remodeling 
 
As can be seen in Figure 23, reactive ductular cells, hepatic progenitor cells and degenerative 
hepatocytes, all involved in hepatic regeneration of seriously damaged tissue express DbpB/YB-1. 
Closer inspection of the DbpB/YB-1staining pattern in patients with HBV-associated cirrhosis 
revealed that immunopositive cells were predominantly found in areas of tissue regeneration and 
nodules from formation (triangles in Figure 25). In contrast, DbpB/YB-1 protein was not detected in 
hepatic tissue without regeneration (stars in Figure 25).   
 
Figure 25. DbpB/YB-1 expression in liver regeneration and tissue remodeling. DbpB/YB-1 IHC staining in patient 
with HBV infection and associated cirrhosis shows that DbpB/YB-1 is mainly expressed of cells forming regenerative 
nodules and areas where hepatic tissue architecture is remodeling (triangle), but not in the healthy-appearing tissues 
(star). 
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3.3.5 TGF-β and IL-13 up-regulate DbpA expression in HSCs 
 
Transforming growth factor-β (TGF-β) is considered to be a major factor contributing to liver 
fibrosis (Massague and Chen 2000) by stimulation of collagen synthesis in hepatic stellate cells 
(HSCs), the major collagen- synthesising cells in the liver. IL-13 also participates in the progress of 
liver fibrosis as a pro-fibrogenic cytokine, as bystander or cofactor acting together with TGF-β 
(Wynn 2003; Liu, Meyer et al. 2011). Given that the DbpA expression closely correlates with the 
early phases of liver fibrogenesis, we stimulate isolated rat primary HSCs with TGF-β and IL-13 in 
vitro. Both cytokines strongly induced DbpA protein expression, as shown in Figure 26. This 
indicates that DbpA expression is linked to profibrogenic TGF-β and IL-13 activites.  
 
 
Figure 26. TGF-β and IL-13 stimulate DbpA protein expression in HSCs. Stimulation of isolated rat primary HSCs 
with TGF-β (5 ng/ml), IL-13 (50 ng/ml) or vehicle for 24, 48 or 72 hours shows up-regulated DbpA protein by 
expression Western-blot. Actin level was taken as loading control.  
 - 78 - 
3.3.6 TGF-β down-regulates DbpB/YB-1 expression in hepatic epithelial cells 
 
As up-regulated DbpB/YB-1 is present in hepatic epithelial cells, i.e. hepatocytes, bile ductular cells, 
and hepatic progenitor cells, we stimulated these cells with the major liver fibrogenic factor TGF-β 
in vitro, and checked DbpB/YB-1 protein expression. As shown in Figure 27, DbpB/YB-1 protein 
expression is suppressed by TGF-β stimulation in all these three cell-types.  
 
 
 
Figure 27. TGF-β suppresses DbpB/YB-1 expression in hepatic epithelial cells. Western-blot analysis of 
DbpB/YB-1 protein expression in cell lysates from TGF-β (5 ng/ml) stimulated rat primary hepatocytes (A), human 
cholangiocyte cell line MMNK-1 (B) and mouse liver progenitor cells (C). 
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3.3.7 DbpB/YB-1 protein expression negatively correlates with EMT  
 
Besides the stimulatory effects on collagen production in HSCs, TGF-β is also considered to be an 
inducer of epithelial to mesenchymal transition (EMT) in hepatic epithelial cells and plays 
important roles in liver fibrogenesis, carcinogenesis and tumor metastasis formation. In sequential 
tissue slices we observed an inverse correlation between DbpB/YB-1 protein expression and 
number of cells having completed EMT, as assessed by staining for mesenchymal cell-specific 
marker proteins Snail and S100A4 (Figure 28). In vitro incubation of hepatic progenitor cells with 
TGF-β induced EMT as assessed by reduced E-cadherin level and increased Twist1 expression. At 
the same time DbpB/YB-1 protein expression was suppressed (Figure 29). 
 
Figure 28. DbpB/YB-1 negatively correlates with EMT in vivo. Immunohistochemistry of HBV infected cirrhosis 
liver as well as HCC tissue. DbpB/YB-1 protein expression does not co-localize with EMT marker proteins Snail and 
S100A4. 
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Figure 29. DbpB/YB-1 protein levels negatively correlate with EMT in vitro. Western blot analysis of E-cadherin, 
Twist1 and DbpB/YB-1 protein was performed with cell extracts from liver progenitor cells grown in the absence or 
presence of TGF-β (5 ng/ml, for 72 or 96 hours). DbpB/YB-1 protein expression was suppressed while EMT marker 
Twist1 was up-regulated and E-cadherin is down-regulated. 
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3.3.8 DbpB/YB-1 is up-regulated in liver steatosis  
 
DbpB/YB-1 up-regulation is not restricted to HBV infected fibrotic liver diseases, IHC performed 
in 3 patients diagnosed with liver steatosis also revealed pronounced YB-1 immunopositivity in all 
3 cases (Figure 30). Similar results were obtained with liver tissue from animals that were 
challenged with alcohol for 4 weeks (Figure 31). Up-regulated DbpB/YB-1 protein expression was 
localized in hepatic epithelial cells.  
 
Figure 30. DbpB/YB-1 expression is up-regulated in liver tissue of steatosis patients. IHC staining of DbpB/YB-1 
in liver biopsies from patient diagnosed with liver steatosis shown in 100x (a) and 200x (b) magnification.  
 
 
Figure 31. DbpB/YB-1 protein expression is up-regulated in an experimental steatosis model. DbpB/YB-1 was 
visualized by IHC in liver tissue of mice challenged with alcohol (4 weeks). Diffuse cytoplasmic DbpB/YB-1 staining 
is detected in hepatocytes of alcohol challenged animals with steatosis, however not in control animals.  
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3.4 Cloning of DbpA and DbpB/YB-1 gene promoter constructs 
 
The expression of DbpA and DbpB/YB-1 proteins are strongly regulated in inflammatory kidney 
and liver diseases. In order to unravel transcriptional regulatory mechanisms of human CSPs, 
different lengths of promoter regions from the human DbpA and DbpB/YB-1 genes were cloned 
into a luciferase reporter plasmid. According to the homologies of DbpA and DbpB/YB-1 promoter 
regions between human, mouse and rat, serial 5′-deleted promoter constructs were designed, as 
shown in Figure 32. Using primers pairs (Table 7) target DNA fragments are amplified by PCR 
(shown in Figure 33) and cloned into luciferase reporter plasmid pGL4.10.  
 
 
Figure 32. Schematic representation of DbpA and DbpB/YB-1 promoter constructs. Six promoter regions 
beginning at -1633, -1096, -964, -668, -527, and -173 bp upstream of the translation initiation site of the DbpA gene (A) 
as well as six regions beginning at -1396, -1060, -513, -230, -144, and -27 bp upstream of the DbpB/YB-1 gene and 
spanning to bp 284 (B) were cloned into a luciferase reporter plasmid pGL4.10.  
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Figure 33. DbpA and DbpB/YB-1 promoter constructs. By means of PCR the target DNA fragments of DbpA and 
DbpB/YB-1 promoters were amplified. Results were confirmed by electrophoresis.   
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4 Discussion 
 
The present work sets out to analyze cold shock protein expression and regulation in inflammatory 
kidney and liver diseases. As major finding we observe a strong up-regulation of cold shock protein 
DbpA in mesangioproliferative nephritis in a pattern that resembles the one observed with 
DbpB/YB-1 (van Roeyen, Eitner et al. 2005; Frye, Halfter et al. 2009). There is a strong 
up-regulation of CSP within the mesangial compartment as down-stream targets of PDGF-B 
signaling. It indicates that DbpA and DbpB/YB-1 may play similar roles in mesangioproliferative 
GN. On the other hand, both DbpA and DbpB/YB-1 expression were found to be up-regulated in 
fibrotic liver tissues, however with different expression patterns. This may indicate different roles 
that CSPs play in the course of inflammatory liver diseases. 
 
4.1 PDGF-BB as inducer of CSP expression in mesangial cells 
 
PDGF-B is one of the most potent mitogens for mesangial cells and plays a crucial role in 
mesangioproliferative diseases (Floege, Ostendorf et al. 1999; Floege, Eitner et al. 2008). PDGF-B 
activates down-stream signaling, including the MAPK pathway. Inhibition of the MAPK/ERK 
pathway by U0126 leads to significant disease amelioration. Blockade of either PDGF-B by 
aptamers or MAPK/ERK signaling by U0126 is accompanied by down-regulated DbpA expression. 
Similar effects have been reported for DbpB/YB-1 (van Roeyen, Eitner et al. 2005).  
 
The MAPK/ERK pathway activates various proto-oncogenes, e.g. c-fos, c-myc and c-jun 
(Choudhury, Karamitsos et al. 1997; Choudhury, Ghosh-Choudhury et al. 1998), that may regulate 
human CSP expression via the following mechanisms: On the one hand it has been reported that 
c-myc directly stimulates both DbpA and DbpB/YB-1 transcription (Li, Van Calcar et al. 2003). On 
the other hand, c-fos dimerizes with c-jun to form AP-1 complexes that may release the E2F 
transcription factors via activation of Cyclin D1/Cdk4 and phosphorylating of pRb (Shen, Uray et al. 
2008). Among the various E2F transcription factors E2F1 has been reported to be crucial for 
mesangial cell proliferation (Inoshita, Terada et al. 1999) and of notably E2F1 is a direct 
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transcriptional inducer of the DbpA gene (Arakawa, Kajino et al. 2004). The scheme in Figure 36 
shows signaling events that may regulate human CSP expression following PDGF-BB stimulation.  
 
Figure 36.  Scheme of signaling events regulating cold shock protein (CSP) expression following PDGF-BB 
stimulation. PDGF-BB signals via binding to its receptor that dimerizes and activates MEK and extracellular receptor 
kinases (ERK). A known target molecule involves the proto-oncogene c-myc that may up-regulate both DbpA and 
DbpB/YB-1 transcription. Other target molecules include c-fos and c-jun that may activate E2F1 via the Cyclin 
D1/CDK4 complex. E2F1 may enhance DbpA transcription by binding to its promoter sequences. CSP may function as 
transcription factors in the nucleus, as translation factors in the cytoplasm, as well as mitogens or chemoattractants in 
the extracellular compartment. 
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4.2 Possible roles of DbpA in mesangioproliferative diseases 
 
Mesangial cell proliferation is the key pathological feature in mesangioproliferative diseases. 
DbpB/YB-1 has been previously reported to promote mesangial cell (MC) proliferation as a 
mediator of PDGF-B signaling (van Roeyen, Eitner et al. 2005). Considering the similar expression 
and regulation patterns of both CSP in mesangioproliferative diseases, DbpA may play similar roles 
as DbpB/YB-1. A pro-mitogenic role of DbpA has been reported in several malignant diseases. The 
expression of DbpA is up-regulated in hepatocellular carcinoma (HCC) (Hayashi, Kajino et al. 2002; 
Arakawa, Kajino et al. 2004; Yasen, Kajino et al. 2005) and gastric cancer (Wang, Zheng et al. 
2009). Over-expressed DbpA is associated with advanced stages of hepatocellular carcinoma and 
nuclear translocation of DbpA may indicate poor prognosis (Yasen, Kajino et al. 2005). In chronic 
myeloid leukemia (CML) phosphorylation of DbpA at Ser134 is reported to be crucial for Bcr-Abl 
mediated CML-associated cell proliferation and leukemogenesis, though increased DbpA 
expression is not mentioned (Sears, Luong et al. 2010). Studies also show that DbpA is an 
important factor in breast cancer (Sharp, Mailer et al. 2008), oveal melanoma (Jayagopal, Yang et 
al.) and colorectal cancinoma (Buchert, Papin et al. 2010; Dhawan, Ahmad et al. 2011). 
DbpA-dependent cell proliferation is not only observed in cancer cells. Recent studies show that 
DbpA expressing and nuclear accumulation is crucial for tubular cell proliferation in the kidney 
(Lima, Parreira et al. 2010). Several regulation mechanisms may be involved in DbpA-mediated 
cell proliferation. For instance DbpA is directly regulated by proliferation-associated transcription 
factors, e.g. c-myc (Li, Van Calcar et al. 2003) and E2F1 (Arakawa, Kajino et al. 2004). c-myc is 
one of the most studied cancer genes. E2F1 is known to be important for cell proliferation, for the 
transition of cells from G1 to S phase (Johnson, Schwarz et al. 1993; Cam and Dynlacht 2003). 
DbpA interacts with guanine nucleotide exchange factor (GEF-H1) and may mediate Rho-regulated 
G1-S transition in the cell cycle (Nie, Aijaz et al. 2009). By acting as a transcription factor, DbpA 
may directly bind to the promoter region of several proliferation-associated genes, including 
epidermal growth factor receptor (EGFR) (Sakura, Maekawa et al. 1988), thymidine kinase (Kim, 
Lau et al. 1997), cyclin D1 and proliferating cell nuclear antigen (PCNA) (Sourisseau, Georgiadis et 
al. 2006). Thereby it may enhance target gene expression and promote cell proliferation. On the 
other hand, DbpA may directly interact with Cdk4 and inhibit the formation of Cdk4/cyclin D1 
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complexes that inhibit G1/S transition of the cell cycle (Moorthamer, Zumstein-Mecker et al. 1999). 
DbpA transcriptionally up-regulates cyclin D1 expression, but interestingly inhibits cyclin D1 
activity via binding to Cdk4. This may indicate the existence of a DbpA mediated auto-regulatory 
loop that controls cell proliferation (Figure 36). It is possible that when the balance of this loop is 
disrupted by ectopic over-expression or modification of DbpA abnormal proliferation may occur.  
 
In addition to the effects on cell proliferation, DbpA may also play important roles in cell-cell 
communication during the course of mesangioproliferative diseases. Tight junctions (TJs) and gap 
junctions (GJs) are of great importance for cell-cell communication of neighboring cells. Numerous 
studies revealed that DbpA acts as a regulator of TJ- and GJ-associated activities. DbpA has been 
identified as interaction partner of several TJ-assosiated proteins, e.g. ZO-1 (Balda and Matter 
2000), symplekin (Kavanagh, Buchert et al. 2006) and GEF-H1 (Nie, Aijaz et al. 2009). Although 
without direct protein interactions several other TJ-associated proteins have been reported to be 
involved in the regulation of DbpA activities at TJ, e.g. heat-shock protein Apg-2 (Tsapara, Matter 
et al. 2006), B-cell lymphoma 2 (Bcl-2) (Li, Backer et al. 2003), Ras-related protein Ral-A (Frankel, 
Aronheim et al. 2005) and blood vessel epicardial substance (Bves) (Russ, Pino et al. 2011). Apart 
from tight junctions DbpA has been reported to localize at oligodendrocyte and astrocyte gap 
junctions in the mouse brain (Penes, Li et al. 2005) and was found to be associated with 
oligodendrocytic connexin Cx47 and Cx32 as well as with astrocytic Cx43. In Cx47 knock-out 
mice DbpA was absent in oligodendrocytes (Li, Penes et al. 2008). Although mesangial cells do not 
form TJs one of the striking features of MCs is that these cells possess an extremely high density of 
GJs (Barajas, Liu et al. 1994). Yao and colleagues reported that disruption of GJ intercellular 
communication in MCs may be involved in PDGF-B mediated MC proliferation and 
dedifferentiation (Yao, Morioka et al. 2000; Yao, Kitamura et al. 2006). DbpA may play a role in 
this GJ-associated MC proliferation and dedifferentiation. A similar role of DbpA has been 
identified in TJ-associated tubular cell proliferation and dedifferentiation in the kidney (Pannequin, 
Delaunay et al. 2007; Georgiadis, Tschernutter et al. 2010; Lima, Parreira et al. 2010). Furthermore, 
we detected a PDGF-B-dependent secretion of DbpA by rat mesangial cells. Similar extracellular 
release of DbpB/YB-1 protein has been reported. DbpB/YB-1 extracellularly regulates cell-cell 
communication as a mitogen (Frye, Halfter et al. 2009) as well as a ligand of Notch-3 receptor 
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signaling (Rauen, Raffetseder et al. 2009). Considering the similarites between DbpA and 
DbpB/YB-1 in mesangioproliferative GN, secreted DbpA may also act promitogenic, however this 
has not been addressed in the present study.  
 
Recently experimental evidence suggests a pathophysiologic role of endoplasmic reticulum (ER) 
stress in mesangioproliferative glomerulonephritis (Inagi, Kumagai et al. 2008). When mammalian 
cells were subjected to stress that target the endoplasmic reticulum, cells activate a defense 
mechanism referred to as unfolded protein response (UPR), which is evolutionarily conserved from 
yeast to humans (Foti, Welihinda et al. 1999). The major cellular respond to the UPR is an ER 
chaperone, Grp78 (Reddy, Mao et al. 2003). Grp78 not only binds to unfolded proteins but also 
regulates the activation of ER stress signal transducers that protect stressed cells from apoptosis 
(Bertolotti, Zhang et al. 2000). Following induction of anti-Thy1.1 nephritis the expression of 
Grp78 protein in mesangial cells is markedly increased in a time-dependent manner (Inagi, 
Kumagai et al. 2008). DbpA has been identified as a transcriptional regulator that directly binds to 
the core promoter region of the Grp78 gene at the stress-inducible change region (SICR) (Li, 
Hsiung et al. 1997). This assigns DbpA a role in the stress response of mesangial cells in 
mesangioproliferative GN. 
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4.3 Differential expression and regulation of CSPs in inflammatory liver diseases 
 
This is the first report that shows human CSPs are up-regulated in inflammatory liver diseases, e.g. 
HBV associated cirrhosis and steatosis of the liver. However expression patterns of DbpA and 
DbpB/YB-1 differ from each other. DbpA over-expressing cells are identified as activated 
macrophages and activated hepatic stellate cells. In contrast, DbpB/YB-1 immunopositive cells are 
mainly hepatic epithelial cells, i.e. hepatocytes, bile ductular cells and hepatic progenitor cells. 
DbpB/YB-1 staining results were confirmed by different antibodies targeting both the N- and 
C-terminus. For DbpA staining, an antibody specific for the N-terminus was used. In a study from 
Yasen and collegues using an antibody against an epitope within the C-terminus for IHC in HCC 
tissues yielded similar results (Yasen, Kajino et al. 2005). Concerning the different expression 
patterns of CSP in inflammatory liver diseases different functions may be postulated.  
 
4.3.1 DbpA expression correlates with liver fibrogenesis 
 
It has been previously reported that DbpB/YB-1 expression may antagonize TGF-β signaling events 
in activated hepatic stellate cells (HSCs). Thereby it has the propensity to protect the liver from 
fibrosis (Dooley, Said et al. 2006). In fibrotic liver tissue DbpB/YB-1 protein expression was hardly 
detected in HSC by immunohistochemistry. It seems that in HSC of fibrotic liver tissue DbpB/YB-1 
expression as well as its protective effect is suppressed by certain mechanisms, thereby promoting 
fibrogenesis. In contrast, DbpA expression positively correlates with liver fibrogenesis. Its protein 
level is up-regulated in activated HSCs in the early phases of fibrogenesis in vivo. This 
up-regulation was recapitulated in vitro by stimulation of isolated primary HSCs with 
pro-fibrogenic cytokines TGF-β and IL-13. These results indicate that DbpA may be a factor 
promoting liver fibrogenesis, in contrast to DbpB/YB-1. In addition, epithelial cells undergoing 
EMT have been considered as another important source of fibrotic cells. DbpB/YB-1 protein 
expression negatively correlates with EMT in hepatic epithelial cells, which may also indicate a 
protective role of DbpB/YB-1 in liver fibrogenesis.  
 
 - 90 - 
TGF-β, mediated by specific Smad signaling, induces the expression of genes involved in 
extracellular matrix synthesis and plays a major role in liver fibrogenesis (Massague and Chen 
2000). Besides the classic Smad signaling, it is known that TGF-β also activates ERK kinase 
signaling (Lee, Pardoux et al. 2007) and this may contribute to the up-regulation of DbpA 
expression in HSCs by TGF-β. Most of the biological effects of IL-13 are mediated by the IL-4 
receptor and JAK/STAT signaling, particularly STAT6 (Jiang, Harris et al. 2000). However, IL-13 
may also bind to the IL-13α(2) receptor and activate its down-stream signaling events, e.g. 
transcription factor AP-1 (Fichtner-Feigl, Strober et al. 2006), which may up-regulate E2F1 
expression and thereby promote DbpA expression (Arakawa, Kajino et al. 2004; Shen, Uray et al. 
2008).  
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4.3.2 DbpB/YB-1 expression in liver regeneration and re-modeling 
 
The presented preliminary data demonstrate that there is a tight regulation of DbpB/YB-1 protein 
expression in liver cells when they are injured by different challenges, e.g. alcohol or hepatitis B 
viruses. The pathological sequelae of such challenges are denoted liver steatosis, fibrosis and 
cirrhosis, which are major causes of malignant liver diseases. The expression pattern indicates that 
mainly hepatic epithelial cells, but rarely hepatic stellate cells (HSCs), are immunopositive. 
DbpB/YB-1 expressing cells, intermediate hepatocyte-like cells, ductular reaction and hepatic 
progenitor cells, are closely related to liver regeneration and re-modeling. It is observed that 
DbpB/YB-1 expression is elevated in regenerating tissues that forms nodules. In a report from 
Grant et al. several lines of evidence link DbpB/YB-1 expression in the liver with DNA synthesis 
and cell proliferation (Grant and Deeley 1993).  
 
DbpB/YB-1 protein levels were strongly reduced following TGF-β incubation in all three hepatic 
epithelial cells in vitro. However, considering the major functions of TGF-β in hepatic epithelial 
cells (e.g. hepatocytes), that is the suppression of cell proliferation and induction of cell apoptosis 
and transformation (Massague and Chen 2000) it seems contradictory to the known pro-mitogenic 
effects of DbpB/YB-1 in these cell types. This gives rise to the hypothesis that TGF-β and 
DbpB/YB-1 are negatively interrelated. On the other hand, it has been reported that elevated 
DbpB/YB-1 expression in breast cancer cells induces EMT accompanied by enhanced metastatic 
potential and reduced proliferation rates (Evdokimova, Tognon et al. 2009). These findings indicate 
that DbpB/YB-1 may play differential roles in tumor and non-tumor cells. Other mechanisms must 
exist that up-regulate DbpB/YB-1 expression, apart from TGF-β signaling.  
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5 Summary 
Cold shock proteins have attracted considerable attention in the context of carcinogenesis given 
their potent promitogenic roles. The participation of cold shock protein DbpB/YB-1 in the course of 
inflammatory diseases has only recently been described and visualized in experimental models of 
mesangioproliferative glomerular disease and liver fibrotic diseases. The fundamental question 
addressed here is whether another prominent member of the cold shock protein family, DbpA, is 
also regulated in mesangioproliferative disease, although it has been primarily described as protein 
with activities in epithelial tubular cell proliferation and differentiation. Whereas in healthy kidney 
tissue DbpA protein was predominantly detected in vascular small muscle cells a profound 
up-regulation of DbpA protein expression within the mesangial compartment was evidenced in 
human kidney biopsies diagnosed with mesangioproliferative IgA or lupus nephritis. Such a 
mesangial up-regulation was recapitulated in an experimental model, the anti-Thy1.1 nephritis. 
Given the pivotal role of PDGF-B signaling in this disease two interventions were performed, that 
is the application of PDGF-B neutralizing aptamers and MAPK/Erk signaling inhibitor U0126. 
Both interventions resulted in markedly decreased DbpA expression. Conversely, continuous 
PDGF-B infusion induced DbpA expression predominantly within the mesangial compartment in 
rats. In vitro studies of human and rat mesangial cells confirmed the PDGF-B stimulatory effect at 
transcript and protein levels. Notably, DbpA protein isoforms exhibit sizes of 44, 50 and 55 kDa, 
with predominance of the 44 kDa isoform. Conditioned cell culture medium of mesangial cells also 
revealed that PDGF-B induced secretion of DbpA (p50) in a time- and concentration-dependent 
manner occurs. Taken together, cold shock protein DbpA represents a novel target of PDGF-B 
signaling in mesangioproliferative glomerular disease.  
 
In inflammatory liver diseases we observed both DbpA and DbpB/YB-1 up-regulation, however 
with different expression patterns. Whereas DbpA over-expressing cells were identified as activated 
macrophages and hepatic stellate cells, DbpB/YB-1 immunopositive cells were mainly hepatic 
epithelial cells. This may indicate differential roles that CSP fulfill in inflammatory liver diseases: 
DbpA may be functional in the early phases of fibrogenesis while DbpB/YB-1 may be involved in 
liver regeneration and re-modeling. 
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